Clearmind Medicine (CMND) 20-F 29 Jan 24 2023 FY Annual report (foreign) Financial data

Document And Entity Information

Document And Entity Information	12 Months Ended
	Oct. 31, 2023 shares
Document Information Line Items
Entity Registrant Name	Clearmind Medicine Inc.
Trading Symbol	CMND
Document Type	20-F
Current Fiscal Year End Date	--10-31
Entity Common Stock, Shares Outstanding	607,337
Amendment Flag	false
Entity Central Index Key	0001892500
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	Oct. 31, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	FY
Entity Emerging Growth Company	true
Entity Shell Company	false
Entity Ex Transition Period	false
ICFR Auditor Attestation Flag	false
Document Registration Statement	false
Document Annual Report	true
Document Transition Report	false
Document Shell Company Report	false
Entity File Number	001-41557
Entity Incorporation, State or Country Code	A1
Entity Address, Address Line One	101 – 1220 West 6th Avenue
Entity Address, City or Town	Vancouver
Entity Address, Country	CA
Entity Address, Postal Zip Code	V6H1A5
Title of 12(b) Security	Common shares, no par
Security Exchange Name	NASDAQ
Entity Interactive Data Current	Yes
Document Financial Statement Error Correction [Flag]	false
Document Accounting Standard	International Financial Reporting Standards
Auditor Firm ID	1197
Auditor Name	Brightman Almagor Zohar & Co.
Auditor Location	Tel Aviv, Israel
Business Contact
Document Information Line Items
Entity Address, Address Line One	101 – 1220 West 6th Avenue
Entity Address, City or Town	Vancouver
Entity Address, Country	CA
Contact Personnel Name	Dr. Adi Zuloff-Shani
Entity Address, Postal Zip Code	V6H1A5
City Area Code	973
Local Phone Number	536.1016
Contact Personnel Email Address	invest@clearmindmedicine.com

Consolidated Statements of Fina

Consolidated Statements of Financial Position	Oct. 31, 2023 USD ($)	Oct. 31, 2022 USD ($)
Current assets
Cash and cash equivalents	$ 5,427,739	$ 128,777
Other receivables	104,320	50,933
Short-term investment (Note 5)	86,112	193,750
Prepaid expenses	40,403	14,245
Related parties (Note 6b)	136,002	46,988
Total current assets	5,794,576	434,693
Non-current assets
Property and equipment	1,727	12,902
Intangible assets (Note 3)	119,310	130,264
Restricted cash	37,675	14,653
Right-of-use asset (Note 4)		35,730
Deferred offering costs		198,173
Total non-current assets	158,712	391,722
Total assets	5,953,288	826,415
Current liabilities
Accounts payable and accrued liabilities	617,004	1,396,960
Due to related parties (Note 6)	42,433	206,494
Derivative warrants liabilities (Note 7)	4,310,379
Derivative liability (Note 8d (iii))		290,569
Lease liability (Note 4)		38,390
Total liabilities	4,969,816	1,932,413
Shareholders’ equity (deficit)
Share capital and share premium (Note 8)	17,131,223	6,706,644
Warrants (Note 9)	459,341	459,110
Share-based payment reserve (Notes 10,11)	2,182,221	1,896,724
Accumulated other comprehensive loss	(21,250)	(21,250)
Accumulated deficit	(18,768,063)	(10,147,226)
Total shareholders’ equity (deficit)	983,472	(1,105,998)
Total liabilities and shareholders’ equity (deficit)	$ 5,953,288	$ 826,415

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($)		12 Months Ended
		Oct. 31, 2023	Oct. 31, 2022	Oct. 31, 2021
Operating expenses
General and administrative (Note 17)		$ 4,759,205	$ 3,170,440	$ 2,219,745
Research and development, net (Note 18)		1,544,229	3,080,991	473,652
Total operating expenses		6,303,434	6,251,431	2,693,397
Impairment of exploration and evaluation assets				(7,327)
Finance expenses
Changes in fair value of derivative warrants liabilities (Note 7)		(2,189,986)
Unrealized loss on short-term investment (Note 5)		(107,638)	(308,188)
Foreign exchange loss		(78,136)	(404)	(24,564)
Other finance income (expense), net		59,174	(14,417)
Change in fair value of derivative liability (Note 8d (iii))			(290,569)
Total finance expenses		(2,316,586)	(613,578)	(24,564)
Other income
Dividend received		16,555
Total other income		16,555
Loss Before taxes		(8,603,465)	(6,865,009)	(2,725,288)
Tax expenses		(17,372)	(29,859)
Net Loss		(8,620,837)	(6,894,868)	(2,725,288)
Items that may be reclassified subsequently to profit or loss:
Foreign exchange differences on translation of foreign operations			(21,250)
Comprehensive loss		$ (8,620,837)	$ (6,916,118)	$ (2,725,288)
Loss per share , basic (in Dollars per share)		$ (42.58)	$ (159.11)	$ (88.16)
Weighted average number of shares for the purposes of basic and diluted loss per share (in Shares)	[1]	202,481	43,335	30,911
[1] On September 30, 2022 and on November 28, 2023, the Company effected a 1-for-30 reverse split of its issued and outstanding common shares, pursuant to which holders of the Company’s common shares received 0.0333 of a common share for every one common share. All share amounts have been retroactively restated for all periods presented.

Consolidated Statements of Op_2

Consolidated Statements of Operations and Comprehensive Loss (Parentheticals) - $ / shares	12 Months Ended
	Oct. 31, 2023	Oct. 31, 2022	Oct. 31, 2021
Profit or loss [abstract]
Loss per share , diluted	$ (42.58)	$ (159.11)	$ (88.16)
Weighted average number of shares for the purposes of diluted loss per share	202,481	43,335	30,911

Statements of Changes in Shareh

Statements of Changes in Shareholders’ Equity (Deficit) - USD ($)		Share capital and share premium		Warrants	Share-based payment reserve	Accumulated other comprehensive income	Accumulated deficit	Total
Balance at Oct. 31, 2020		$ 653,308			$ 107,921		$ (527,070)	$ 234,159
Balance (in Shares) at Oct. 31, 2020	[1]	21,362
Net loss for the year							(2,725,288)	(2,725,288)
Total comprehensive loss for the year								(2,725,288)
Issuance of common shares in private placement		$ 5,659,755						5,659,755
Issuance of common shares in private placement (in Shares)	[1]	20,333
Share issuance costs		$ (521,054)						(521,054)
Issuance of shares in private placement				274,745				274,745
Share issuance costs				(24,178)				(24,178)
Share-based compensation					619,939			619,939
Balance at Oct. 31, 2021		$ 5,792,009		250,567	727,860		(3,252,358)	3,518,078
Balance (in Shares) at Oct. 31, 2021	[1]	41,695
Net loss for the year							(6,894,868)	(6,894,868)
Foreign currency translation gain						(21,250)		(21,250)
Total comprehensive loss for the year						(21,250)	(6,894,868)	(6,916,118)
Common shares issued for services		$ 38,684			107,222			145,906
Common shares issued for services (in Shares)	[1]	89
Units issued for cash		$ 559,118		139,779				698,897
Units issued for cash (in Shares)	[1]	1,325
Share issuance costs		$ (55,912)		(13,978)				(69,890)
Units issued for short-term investment		$ 372,745		82,742				455,487
Units issued for short-term investment (in Shares)	[1]	883
Share-based compensation					1,061,642			1,061,642
Balance at Oct. 31, 2022		$ 6,706,644		459,110	1,896,724	(21,250)	(10,147,226)	$ (1,105,998)
Balance (in Shares) at Oct. 31, 2022		43,992	[1]					43,992
Net loss for the year							(8,620,837)	$ (8,620,837)
Issuance of common shares (Note 8c(i))		$ 6,026,327			337,579			6,363,906
Issuance of common shares (Note 8c(i)) (in Shares)	[1]	38,462
Common shares and warrants issued to Medigus (Note 8c(i))		$ 296,845		231				297,076
Common shares and warrants issued to Medigus (Note 8c(i)) (in Shares)	[1]	1,494
Issuance of common shares, pre-funded warrants and warrants (Note 8c(iii))		$ 1,455,832						1,455,832
Issuance of common shares, pre-funded warrants and warrants (Note 8c(iii)) (in Shares)	[1]	150,191
Issuance of common shares from upon vesting of restricted stock units (Note 8c(ii,v,vii))		$ 263,408			(263,408)
Issuance of common shares from upon vesting of restricted stock units (Note 8c(ii,v,vii)) (in Shares)	[1]	1,391
Issuance of common shares, pre-funded warrants and warrants (Note 8c(viii))		$ 1,069,478						1,069,478
Issuance of common shares, pre-funded warrants and warrants (Note 8c(viii)) (in Shares)	[1]	250,000
Exercise of warrants (Note 7a)		$ 1,164,117						1,164,117
Exercise of warrants (Note 7a) (in Shares)	[1]	119,433
Common shares for services		$ 148,572			(101,888)			46,684
Common shares for services (in Shares)	[1]	2,374
Total comprehensive loss for the year								(8,620,837)
Share-based compensation					313,214			313,214
Balance at Oct. 31, 2023		$ 17,131,223		$ 459,341	$ 2,182,221	$ (21,250)	$ (18,768,063)	$ 983,472
Balance (in Shares) at Oct. 31, 2023	[1]	607,337
[1] On September 30, 2022 and on November 28, 2023, the Company effected a 1-for-30 reverse split of its issued and outstanding common shares, pursuant to which holders of the Company’s common shares received 0.0333 of a common share for every one common share. All share amounts have been retroactively restated for all periods presented.

Consolidated Statements of Cash

Consolidated Statements of Cash Flows	12 Months Ended
	Oct. 31, 2023 USD ($)	Oct. 31, 2022 USD ($)	Oct. 31, 2021 USD ($)
Statement of cash flows [abstract]
Net loss	$ (8,620,837)	$ (6,894,868)	$ (2,725,288)
Adjustments for:
Amortization of intangible assets	10,954	14,830
Amortization of right-of-use asset	35,381	60,665
Interest on lease liability	2,907	14,433
Exchange rate differences	78,171
Issuance costs allocated to derivate warrants liability	468,408
Depreciation of property and equipment	11,175	7,572	1,884
Impairment of exploration and evaluation assets			7,327
Changes in fair value of derivative liabilities	2,189,986	290,569
Share-based compensation	366,405	1,207,549	619,939
Unrealized loss on short-term investment	107,638	308,187
Tax expenses	17,372	29,859
Changes in working capital:
Decrease (increase) in other receivable	(154,621)	19,938	(115,568)
Decrease (increase) in prepaid expenses	(26,134)	103,026	(117,271)
Increase (decrease) in accounts payable and accrued liabilities	(620,421)	913,303	251,738
Increase (decrease) in due to / from related parties	(167,856)	200,443	143
Net cash used in operating activities	(6,301,472)	(3,724,494)	(2,077,096)
Investing activities
Acquisition of property and equipment		(5,563)	(16,961)
Acquisition of intangible assets			(145,094)
Exploration and evaluation asset expenditures			(7,327)
Changes in restricted cash	(26,228)		(14,653)
Net cash used in investing activities	(26,228)	(5,563)	(184,035)
Proceeds from issuance of common shares and warrants, net of issuance costs (Notes 7, 8 c (i,iii,viii))	11,115,241	582,558	5,389,270
Proceeds received from exercise of warrants (Note 7)	590,077
Repayment of lease liabilities	(40,922)	(70,870)
Net cash provided by financing activities	11,664,396	511,688	5,389,270
Effect of foreign exchange rate changes on cash and cash equivalents	(37,734)	(22,652)
Net increase (decrease) in cash and cash equivalents	5,298,962	(3,241,021)	3,128,139
Cash and cash equivalents at beginning of year	128,777	3,369,798	241,659
Cash and cash equivalents at end of year	5,427,739	128,777	3,369,798
Supplementary disclosure of cash flow information:
Cash received for interest	71,733	8
Dividend received	16,555
Cash paid for taxes	12,678
Non-cash financing and investing activities
Common shares issued to Medigus (Note 8d(iii))	296,569
Shares obtained from Medigus in issuance of shares and warrants		455,488
Deferred offering costs included in non-current assets		198,173
Right of use assets obtained in exchange for lease liabilities		$ 92,731

Nature of Operations and Going

Nature of Operations and Going Concern	12 Months Ended
	Oct. 31, 2023
Nature of Operations and Going Concern [Abstract]
Nature of Operations and Going Concern	1. Nature of Operations and Going Concern a. Clearmind Medicine Inc. (the “Company”) was incorporated in the province of British Columbia on July 18, 2017. The Company is a clinical pharmaceutical company approaching phase 1 clinical trials, that develops novel psychedelic medicines to solve widespread, yet under-served, health problems. The Company’s head office is located at Suite 101 -1220 West 6 th On November 14, 2022, the Company completed a public offering for aggregate gross proceeds of $7.5 million and listing on the Nasdaq Capital Market (“Nasdaq”), see note 8c (i). The Company trades under the symbol CMND on both the Nasdaq and the Canadian Securities Exchange (“CSE”) in Toronto and on the Frankfurt Stock Exchange, or FSE, under the symbol “CWY”. On April 6, 2023, the Company completed an underwritten public offering for aggregate gross proceeds of $3.5 million and net proceeds of $2.9 million. See note 8c (iii). On September 18, 2023, the Company completed an underwritten public offering for aggregate gross proceeds of $2.25 million and net proceeds of $1.8 million. See note 8c (viii). On January 16, 2024, the Company completed a registered direct and private placement for aggregate gross proceeds of $2.40 million. See note 19(d). b. Going concern These consolidated financial statements have been prepared on the going concern basis, which assumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of business. For the year ended October 31, 2023, the Company has not generated any revenues and has negative cash flow from operations of $6,301,472. As of October 31, 2023, the Company has an accumulated deficit of $18,768,063. The continued operations of the Company are dependent on its ability to generate future cash flows or obtain additional financing through debt or equity. Management is of the opinion that sufficient working capital will be obtained from external financing to meet the Company’s liabilities and commitments as they become due, although there is a risk that additional financing will not be available on a timely basis or on terms acceptable to the Company. These factors raise substantial doubt on the Company’s ability to continue as a going concern. These consolidated financial statements do not reflect any adjustments that may be necessary if the Company is unable to continue as a going concern. c. Reverse share split On September 30, 2022, the Company’s Board of Directors (the “Board”) approved a 1-for-30 reverse split of its issued and outstanding common shares, effective as of September 30, 2022, pursuant to which holders of the Company’s common shares received 0.0333 of a common share for every one common share. On November 28, 2023, the Company’s Board of Directors (the “Board”) approved a 1-for-30 reverse split of its issued and outstanding common shares, effective as of November 28, 2023, such that each thirty of the Company’s common shares, no par value, were consolidated into one common share, no par value. All issued and outstanding common shares or instruments convertible into common shares contained in these financial statements have been retroactively adjusted to reflect the reverse share split for all periods presented, unless explicitly stated otherwise. d. Functional Currency and Presentation Currency As a result of the Company’s listing on the NASDAQ which was completed in November 2022, the primary economic environment and generation and use of cash flows of the Company became mainly denominated in U.S dollars. Consequently, effective on November 1, 2022, the Company changed both its functional currency and the presentation currency of its consolidated financial statements from the Canadian dollar to the U.S dollar. Clearmind Medicine Inc. is in its research and development stages and has not generated revenues since inception. In consideration of the indicators in IAS 21, the Company determined that the new and future financing activities of the Company and the currency in which cash and cash equivalents are retained were relevant factors indicating that the Canadian dollar will not be the currency to reflect the principal economic environment in which the Company will generate and expend its cash. Under IAS 21, a change in an entity’s functional currency is applied prospectively from the date of the change. The Company applied the practical expedient to apply the transaction procedures applicable to the new functional currency prospectively beginning on November 1, 2022. The change in the functional currency was accounted for prospectively from the date of the change by translating all items of the financial statement into the new functional currency using the exchange rate of $0.7327 CAD/USD at the date of the change. The change in the presentation currency of the consolidated financial statement was accounted for as a change in accounting policy and applied retrospectively, as if the new presentation currency had always been the presentation currency of the consolidation financial statements. Consequently, comparative figures for the years prior to the effective date of November 1, 2022 have been restated to the new presentation currency using the exchange rate in effect on effective date of the change. Following the change in the Company's functional currency, the Company elected, as an accounting policy, not to reclassify instruments which, had had the change in functional currency occurred before initial recognition of the instrument, would have changed its classification. e. On October 7, 2023, an unprecedented attack was launched against Israel by terrorists from the Hamas terrorist organization that infiltrated Israel’s southern border from the Gaza Strip and in other areas within the State of Israel attacking civilians and military targets while simultaneously launching extensive rocket attacks on the Israeli population, which led to the declaration of the ‘Iron Swords’ War (the “War”). The War is on-going as of the issuance date of these financial statements. The Company’s clinical trials, the laboratory that supports such clinical trials and the Contract Research Organization (CRO) are based in Israel. The extent to which the War may impact the Company’s financial condition, results of operations, or liquidity is uncertain, and as of the date of issuance of these consolidated financial statements, the Company is not aware of any specific event or circumstance that would require an update to its estimates or judgments or an adjustment to the carrying value of the Company’s assets or liabilities as of October 31, 2023.

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Oct. 31, 2023
Significant Accounting Policies [Abstract]
Significant Accounting Policies	2. Significant Accounting Policies a. Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (“IFRS”), as issued by the International Accounting Standards Board (“IASB”) on a going concern basis. These consolidated financial statements include the accounts of the Company and its 100% owned subsidiaries, Clearmindmed Ltd. and Clearmind Labs Corp. (inactive). All inter-company balances and transactions have been eliminated on consolidation. These consolidated financial statements have been prepared on a historical cost basis, except for financial assets and liabilities (including derivatives) which are presented at fair value through profit or loss (“FVTPL”), and are presented in United States dollars, which is the Company’s functional currency as of November 1, 2022. b. Significant Accounting Estimates and Judgments The preparation of consolidated financial statements in accordance with IFRS requires management to make judgments, estimates, and assumptions that affect the application of policies and reported amounts of assets, liabilities, income, and expenses. The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making the judgments about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates. Significant Estimates Share-based Compensation Fair values are determined using the Black-Scholes option pricing model. Estimating fair value requires determining the most appropriate valuation model for a grant of equity instruments, which is dependent on the terms and conditions of the grant. Option-pricing models require the use of highly subjective estimates and assumptions including the expected stock price volatility. Changes in the underlying assumptions can materially affect the fair value estimates and, therefore, existing models do not necessarily provide reliable measurement of the fair value of the Company’s stock options. Warrant Liability The Company analyses warrants issued to determine whether they meet the classification as liabilities or equity. Derivative warrant liabilities are adjusted to reflect fair value at each reporting period, with any increase or decrease in the fair value recorded in the results of operations. The Company uses a fair valuation specialist to estimate the value of these instruments using the Black and Scholes and binomial pricing model. The key assumptions used in the models are the expected future volatility in the price of the Company's shares, the expected life of the warrants and the probability of any future adjustment event. Significant Judgments The critical judgments that the Company’s management has made in the process of applying the Company’s accounting policies that have the most significant effect on the amounts recognized in the Company’s consolidated financial statements are as follows: Going Concern The application of the going concern assumption requires management to take into account all available information about the future, which is at least but not limited to, 12 months from the year end of the reporting period. The Company is aware that material uncertainties related to events or conditions raise substantial doubt upon the Company’s ability to continue as a going concern. c. Cash and Cash Equivalents The Company considers all highly liquid instruments with a maturity of three months or less at the time of issuance, which are readily convertible to known amounts of cash, and which are subject to insignificant risk of changes in value to be cash equivalents. d. Provisions Provisions are recognized where a legal or constructive obligation has been incurred as a result of past events; it is probable that an outflow of resources embodying economic benefit will be required to settle the obligation; and a reliable estimate of the amount of the obligation can be made. Provisions are measured at the present value of the expenditures expected to be required to settle the obligation. e. Property and Equipment Property and equipment are stated at cost less accumulated depreciation and accumulated impairment losses. Cost includes expenditures that are directly attributable to the acquisition of the asset. Subsequent costs are included in the asset’s carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Company and the cost can be measured reliably. The carrying amount of a replaced asset is derecognized when replaced. Repairs and maintenance costs are charged to the consolidated statements of operations and comprehensive loss during the period in which they are incurred. Depreciation of property and equipment is provided using the straight-line method at the following rates approximating their estimated useful lives: Research and development equipment 3 years Computer equipment 3 years f. Intangible Assets Intangible assets consist of patents and patent applications acquired to be used in drug research programs. Intangible assets are carried at cost less accumulated amortization and impairment losses and are capitalized when the costs can be measured reliably, and it is probable that future economic reliably benefits that are attributable to the asset will flow to the Company. The Company amortizes patents over the term of the patent. g. Impairment of Non-Current Assets At each reporting date, the Company reviews the carrying amounts of its non-current assets to determine whether there are any indications of impairment. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment, if any. Where the asset does not generate cash flows that are independent from other assets, the Company estimates the recoverable amount of the cash generating unit (“CGU”) to which the asset belongs. The recoverable amount is determined as the higher of fair value less direct costs to sell and the asset’s value in use. In assessing value in use, the estimated future cash flows are discounted to their present value. Estimated future cash flows are calculated using estimated recoverable reserves, estimated future commodity prices and the expected future operating and capital costs. The pre-tax discount rate applied to the estimated future cash flows reflects current market assessments of the time value of money and the risks specific to the asset for which the future cash flow estimates have not been adjusted. If the carrying amount of an asset or CGU exceeds its recoverable amount, the carrying amount of the asset or CGU is reduced to its recoverable amount through an impairment charge to the consolidated statement of operations and comprehensive loss. Assets that have been impaired are tested for possible reversal of the impairment whenever events or changes in circumstance indicate that the impairment may have reversed. When an impairment subsequently reverses, the carrying amount of the asset or CGU is increased to the revised estimate of its recoverable amount, but only so that the increased carrying amount does not exceed the carrying amount that would have been determined (net of depreciation, depletion and amortization) had no impairment loss been recognized for the asset or CGU in prior periods. A reversal of impairment is recognized as a gain in the consolidated statement of operations and comprehensive loss. h. Financial Instruments Financial assets and financial liabilities are recognized when the Company becomes a party to the contractual provisions of the respective instrument. Financial assets and financial liabilities are initially measured at fair value. Transaction costs that are directly attributable to the acquisition or issuance of financial assets and financial liabilities (other than financial assets and financial liabilities at FVTPL) are included in the initial carrying value of the related instrument and are amortized using the effective interest method. Transaction costs directly attributable to the acquisition of financial assets or financial liabilities at FVTPL are recognized immediately in the consolidated statement of operations and comprehensive loss. Financial assets The classification of financial assets depends on the nature and purpose of the financial assets and is determined at the time of initial recognition. Financial assets at FVTPL Financial assets are classified as FVTPL when the financial asset is either held for trading or it is designated as FVTPL. A financial asset is classified as held for trading if: ● it has been acquired principally for the purpose of selling it in the near term; or ● on initial recognition it is part of a portfolio of identified financial instruments that the Company manages together and has a recent actual pattern of short-term profit-taking. Financial assets at amortized cost Financial assets at amortized cost are non-derivative financial assets which are held within a business model whose objective is to hold assets to collect contractual cash flows and its contractual terms give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. A financial asset (unless it is a trade receivable without a significant financing component that is initially measured at the transaction price) is initially measured at fair value plus, for an item not at FVTPL, transaction costs that are directly attributable to its acquisition. Subsequent to initial recognition, financial assets are measured at amortized cost using the effective interest method, less any impairment. Financial liabilities and equity instruments Classification as debt or equity Debt and equity instruments issued by the Company are classified as either financial liabilities or as equity in accordance with the substance of the contractual arrangements and the definitions of a financial liability and an equity instrument. Equity instruments An equity instrument is any contract that evidences a residual interest in the assets of an entity after deducting all of its liabilities. Equity instruments issued by the Company are recognized as the proceeds received, net of direct issue costs. Other financial liabilities All financial liabilities are measured subsequently at amortized cost using the effective interest method or at FVTPL. Financial liabilities at FVTPL Financial liabilities are classified as at FVTPL when the financial liability is (i) contingent consideration of an acquirer in a business combination, (ii) held for trading or (iii) it is designated as at FVTPL. A financial liability is classified as held for trading if either: ● It has been acquired principally for the purpose of repurchasing it in the near term ● On initial recognition it is part of a portfolio of identified financial instruments that the group manages together and has a recent actual pattern of short-term profit-taking ● It is a derivative, except for a derivative that is a financial guarantee contract or a designated and effective hedging instrument Financial liabilities at FVTPL are measured at fair value, with any gains or losses arising on changes in fair value recognized in profit or loss. Financial liabilities measured subsequently at amortized cost Financial liabilities that are not (i) contingent consideration of an acquirer in a business combination, (ii) held-for-trading, or (iii) designated as at FVTPL, are measured subsequently at amortized cost using the effective interest method. The effective interest method is a method of calculating the amortised cost of a financial liability and of allocating interest expense over the relevant period. The effective interest rate is the rate that exactly discounts estimated future cash payments (including all fees and points paid or received that form an integral part of the effective interest rate, transaction costs and other premiums or discounts) through the expected life of the financial liability, or (where appropriate) a shorter period, to the amortised cost of a financial liability. i. Income Taxes Current income tax The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in profit or loss because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The Company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period. Deferred income tax Deferred income tax is provided using the statement of financial position method on temporary differences at the reporting date between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes. The carrying amount of deferred income tax assets is reviewed at the end of each reporting period and recognized only to the extent that it is probable that sufficient taxable income will be available to allow all or part of the deferred income tax asset to be utilized. Deferred income tax assets and liabilities are measured at the tax rates that are expected to apply to the year when the asset is realized or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period. Deferred income tax assets and deferred income tax liabilities are offset, if a legally enforceable right exists to set off current tax assets against current income tax liabilities and the deferred income taxes relate to the same taxable entity and the same taxation authority. j. Foreign Currency Translation The Company’s reporting currency is the United States dollar. The functional currency for the Company and its subsidiary is the currency of the primary economic environment in which the entity operates. As of November 1, 2023, the functional currency of the Company and its Canadian and Israeli subsidiaries is the United States dollar. Transactions denominated in currencies other than the functional currency are translated using the exchange rate in effect on the transaction date or at the annual average rate. Monetary assets and liabilities denominated in foreign currencies are retranslated at the rate of exchange in effect at the consolidated statement of financial position date. Non-monetary items are translated using the historical rate on the date of the transaction. Foreign exchange gains and losses are included in the consolidated statement of operations and comprehensive loss. k. Share-based Payments The grant date fair value of share-based payment awards granted to employees is recognized as stock-based compensation expense, with a corresponding increase in equity, over the period that the employees unconditionally become entitled to the awards. The amount recognized as an expense is adjusted to reflect the number of awards for which the related service and non-market vesting conditions are expected to be met, such that the amount ultimately recognized as an expense is based on the number of awards that do meet the related service and non-market performance conditions at the vesting date. For share-based payment awards with non-vesting conditions, the grant date fair value of the share-based payment is measured to reflect such conditions and there is no true-up for differences between expected and actual outcomes. Where equity instruments are granted to parties other than employees, they are recorded by reference to the fair value of the services received. If the fair value of the services received cannot be reliably estimated, the Company measures the services received by reference to the fair value of the equity instruments granted, measured at the date the counterparty renders service. The fair value of services received from consultants cannot be reliably measured; therefore, the fair value of the underlying equity instruments was utilized for all periods presented. All equity-settled share-based payments are reflected in share-based payment reserve, unless exercised. Upon exercise, shares are issued and the amount reflected in share-based payment reserve is credited to share capital, adjusted for any consideration paid. l. Restricted Share Units The Company recognizes compensation expense for restricted share units (“RSU’s”) awarded based on the grant-date fair value of the common shares. The grant-date fair value, which is determined by multiplying the Company’s share price by the number of RSU’s granted, is amortized over the vesting period and is included in compensation expense with a corresponding increase in the share-based payment reserve. If RSU’s are for services that have been provided and are non-cancellable, the Company recognizes the full cost of the RSU’s on the date of grant. The amount recognized is adjusted to reflect the number of RSU’s expected to eventually vest. m. Leases The Company’s Israeli subsidiary leased an office through to June 30, 2023. At inception of a contract, the Company assesses whether a contract is, or contains, a lease. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. The Company reassesses whether a contract is, or contains, a lease only if the terms and conditions of the contract are changed. At the commencement date, the Company measures the lease liability at the present value of the lease payments that are not paid at that date, including, inter alia, the exercise price of a purchase option if the Company is reasonably certain to exercise that option. Simultaneously, the Company recognizes a right-of-use (“ROU”) asset in the amount of the lease liability. The discount rate applied by the Company is the rate of interest that the Company would have to pay to borrow over a similar term, and with a similar security, the funds necessary to obtain an asset of a similar value to the ROU asset in a similar economic environment. The weighted average of lessee’s incremental annual borrowing rate applied to the lease liabilities as of June 30, 2023 was estimated at 20%. The lease term is the non-cancellable period for which the Company has the right to use an underlying asset, together with both, the periods covered by an option to extend the lease if the Company is reasonably certain to exercise that option and periods covered by an option to terminate the lease if the Company is reasonably certain not to exercise that option. After the commencement date, the Company measures the ROU asset applying the cost model, less any accumulated depreciation and any accumulated impairment losses and adjusted for any remeasurement of the lease liability. Assets are depreciated by the straight-line method over the estimated useful lives of the ROU asset or the lease period, whichever is shorter. Interest on the lease liability is recognized in profit or loss in each period during the lease term in an amount that produces a constant periodic rate of interest on the remaining balance of the lease liability. The Company applied the following practical expedients: ● Non-lease components: practical expedient by class of underlying asset not to separate non-lease components (services) from lease components and, instead, account for each lease component and any associated non lease components as a single lease component. ● The practical expedient for short-term leases is applied. n. Employee benefits 1) Pension and retirement benefit obligations The Company operates a number of post-employment defined contribution plans. A defined contribution plan is a program that benefits an employee after termination of employment, under which the Company regularly makes fixed payments to a separate and independent entity so that the Company has no legal or constructive obligation to pay additional contributions if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods. The fund assets are not included in the Company’s statement of financial position. The Company operates pension and severance compensation plans subject to Section 14 of the Israeli Severance Pay Law. The Option Plans are funded through payments to insurance companies or pension funds administered by trustees. In accordance with its terms, the Option Plans meet the definition of a defined contribution plans as defined above. The expenses in respect of defined contribution plans during the years ended October 31, 2023, 2022 and 2021 were $13,988, $31,157 and $50,661, respectively. 2) Vacation and recreation pay Under Israeli law, each employee is entitled to vacation days and recreation pay, both computed on an annual basis. The entitlement is based on the period of employment. The Company records a liability and an expense for vacation and recreation pay, based on the benefit accumulated for each employee. o. Research and Development Research costs are charged to operations as incurred. Development activities involve a plan or design for the production of new or substantially improved products and processes. Development expenditures are capitalized only if development costs can be measured reliably, the product is technically and commercially feasible, future economic benefits are probable, and the Company intends to or has sufficient resources to complete development and to use or sell the asset. The expenditure capitalized includes the cost of materials, direct labor and overhead costs that are directly attributable to preparing the asset for its intended use and borrowing costs on qualifying assets. Other development expenditures are recognized in the consolidated statement of operations and comprehensive loss as incurred. The Company has not capitalized any development costs for the years ended October 31, 2023, 2022 and 2021. p. Loss Per Share Basic loss per share is computed using the weighted average number of common shares outstanding during the period. The treasury stock method is used for the calculation of diluted loss per share, whereby all “in the money” stock options and share purchase warrants are assumed to have been exercised at the beginning of the period and the proceeds from their exercise are assumed to have been used to purchase common shares at the average market price during the period. When a loss is incurred during the period, basic and diluted loss per share is the same as the exercise of stock options and share purchase warrants is considered to be anti-dilutive. As of October 31, 2023, the Company had 833,810 (2022 – 26,419, 2021- 21,507) potentially dilutive shares outstanding. q. The Company capitalizes certain legal and other third-party fees that are directly related to the Company’s in- process equity financing until such financing is consummated. After consummation of such equity financing, these costs are recorded as a reduction of the respective gross proceeds. Should a planned equity financing be abandoned, terminated or significantly delayed, the deferred offering costs are written off to operating expenses. Where the financing includes both an equity and liability component, pro-rata issuance costs relating to the liability component are charged to the statement of operations. r. Accounting Standards Issued But Not Yet Effective i) Amendments to IAS 1 Presentation of Financial Statements— The IASB issued a narrow-scope amendment to IAS 1, in January 2020, to clarify that liabilities are classified as either current or non-current, depending on the rights that exist at the end of the reporting period. The amendment could affect the classification of liabilities, particularly for entities that previously considered management’s intentions to determine classification and for some liabilities that can be converted into equity. Inter alia, the amendment requires the following: Liabilities are classified as non-current if the entity has a substantive right to defer settlement for at least 12 months at the end of the reporting period. The amendment no longer refers to unconditional rights. The assessment determines whether a right exists, but it does not consider whether the entity will exercise the right. ’Settlement’ is defined as the extinguishment of a liability with cash, other economic resources or an entity’s own equity instruments. There is an exception for convertible instruments that might be converted into equity, but only for those instruments where the conversion option is classified as an equity instrument as a separate component of a compound financial instrument. The amendments are applied retrospectively for annual periods beginning on or after 1 January 2024, with early application permitted. ii) Amendments to IAS 1 Presentation of Financial Statements and IFRS Practice Statement 2 Making Materiality Judgements - Disclosure of Accounting Policies The amendments change the requirements in IAS 1 with regard to disclosure of accounting policies. The amendments replace all instances of the term ‘significant accounting policies’ with ‘material accounting policy information’. Accounting policy information is material if, when considered together with other information included in an entity’s financial statements, it can reasonably be expected to influence decisions that the primary users of general-purpose financial statements make on the basis of those financial statements. The supporting paragraphs in IAS 1 are also amended to clarify that accounting policy information that relates to immaterial transactions, other events or conditions is immaterial and need not be disclosed. Accounting policy information may be material because of the nature of the related transactions, other events or conditions, even if the amounts are immaterial. However, not all accounting policy information relating to material transactions, other events or conditions is itself material. The IASB has also developed guidance and examples to explain and demonstrate the application of the ‘four-step materiality process’ described in IFRS Practice Statement 2. The amendments are applied for annual periods beginning on or after January 1, 2023.

Intangible Assets

Intangible Assets	12 Months Ended
	Oct. 31, 2023
Intangible Assets [Abstract]
Intangible Assets	3. Intangible Assets On May 4, 2021, the Company entered into an assignment agreement to acquire certain intellectual property including a patent for “Binge Behavior Regulators,” which has been granted in the U.S., Europe, China and India, with pending divisional applications in Europe and the U.S, and a patent for “Alcohol Beverage Substitute,” which has been approved for a European patent, with pending applications in the U.S., China and India. In consideration for the acquired intellectual property, the Company paid $160,000. The patents are amortized over their estimated remaining life of 14.6 years.

Leases

Leases	12 Months Ended
	Oct. 31, 2023
Leases [Abstract]
Leases	4. Leases On July 1, 2021, the Company entered into a lease agreement (“2021 Lease”) with Scisparc Ltd, a related party (“Scisparc”) and a third party for a total area of approximately 240m 2 2 The lease expired on June 30, 2023. As of October 31, 2023 the Company and SciSparc were in the process of negotiating the terms of a new lease contract. On December 25, 2023, the rental agreement was renewed for a further 18 months. The Company’s base rent was increased to ILS 23,300 per month ($6,500). See Note 6b. As of October 31, 2023, the Company has a pledge on its short-term deposit in favor of an Israeli bank in the amount of approximately $33 thousand to secure the Company’s lease commitment. ROU Balance, October 31, 2022 $ 35,730 Addition - Accumulated depreciation (35,381 ) Foreign currency fluctuation (349 ) Balance, October 31, 2023 $ - Lease Balance, October 31, 2022 $ 38,390 Addition - Lease payments (40,922 ) Interest expense 2,907 Foreign currency translation (375 ) Balance, October 31, 2023 $ - Amounts recognized in profit or loss Year ended October 31, 2023 Depreciation $ 35,381 Interest 2,907 Foreign currency fluctuation 722 $ 39,010

Short-term Investment

Short-term Investment	12 Months Ended
	Oct. 31, 2023
Short-term Investment [Abstract]
Short-term Investment	5. Short-term Investment Pursuant to the Share Exchange Agreement (as defined in Note 8d(iii)) with Medigus Ltd (“Medigus”), on February 14, 2022, the Company received 27,778 (*) ordinary shares of Medigus (the “Medigus Agreement”). As of October 31, 2023, the Company holds 27,778 ordinary shares of Medigus (approximately 0.11%) with a total fair value of $86,112. The fair value of ordinary shares held was determined by reference to public price quotations in an active market. See Note 12. October 31, Additions Unrealized October 31, Medigus Ltd. – Shares $ 193,750 $ - $ (107,638 ) $ 86,112 October 31, Additions Unrealized October 31, Medigus Ltd. – Shares $ - $ 501,938 $ (308,188 ) $ 193,750 * The share amount is following the Medigus 1:15 share split from November 14, 2022.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Oct. 31, 2023
Related Party Transactions [Abstract]
Related Party Transactions	6. Related Party Transactions a. Compensation to key management personnel (i) The compensation to key management personnel for employment services they provide to the Company is as follows: Year ended Year ended Year ended October 31, October 31, October 31, 2023 2022 2021 Officers: Payroll and other short-term benefits $ - $ 32,533 $ 297,188 Consulting fees 410,066 453,519 49,820 Share based compensation 124,808 772,786 179,996 $ 534,874 $ 1,258,838 $ 527,004 Directors: Directors’ fees $ 182,261 $ 124,746 $ 38,098 Share based compensation 121,981 43,485 17,218 $ 304,242 $ 168,231 $ 55,316 (ii) Balances with related parties October 31, October 31, 2023 2022 Amounts owed to officers $ 29,666 $ 136,149 Amounts owed to directors 12,767 70,345 $ 42,433 $ 206,494 b. On March 7, 2022, the Company signed an agreement with SciSparc Ltd (“SciSparc”), pursuant to which the Company and SciSparc agreed to cooperate in conducting a feasibility study using certain molecules developed by each party (the “Cooperation Agreement”). Certain of the Company’s officers and directors currently operate, manage or are engaged as officers and/or directors of SciSparc. In June 2023, the Company entered into a research agreement with the Hebrew University of Jerusalem to evaluate our and SciSparc’s combination treatment for obesity and metabolic syndrome. To date, the collaboration has resulted in the filing of nine patent applications. To the extent the parties determine to proceed to a commercial cooperation, they will enter into a joint venture where the parties share the economics and rights on a 50%-50% basis. To date, no determination has been made to pursue the joint venture and the development of the molecule remains in a very early stage. For the year ended October 31, 2023, the Company incurred research and development expenses conducted within the framework of the Cooperation Agreement in the amount of $131,409, $194,205 and nil c. The Company shares office space with SciSparc and participates for paying office expenses– see Note 4.

Derivative Warrants Liabilities

Derivative Warrants Liabilities	12 Months Ended
	Oct. 31, 2023
Derivative Warrants Liability Abstract
Derivative Warrants Liabilities	7. Derivative warrants liabilities a. On April 6, 2023, the Company issued 150,191 warrants in connection with its April 2023 Public Offering (“April 2023 Warrants”). The warrant includes a cashless exercise provision and repricing adjustments for offerings at a price lower than the existing exercise price of the warrants, stock splits, reclassifications, subdivisions, and other similar transactions (“April 2023 Warrant Adjustments”) and therefore, these warrants were recorded at their fair value as a derivative liability and the time of the grant and are revalued at the end of each reporting period. On September 24, 2023, following the September 2023 Public Offering, which included the offering of common shares at a price lower than the exercise price of the April 2023 Warrants, the exercise price of the April 2023 Warrants was reduced to $5.124, and each April 2023 Warrant became convertible into 4.6 common shares of the Company. During the period between October 17, 2023 and October 20, 2023, 26,153 April 2023 Warrants with a fair value of $574,040 were exercised into 119,433 common shares. (See note 19(b)). b. On September 18, 2023, the Company issued 250,000 warrants in connection with its September 2023 Public Offering (“September 2023 Warrants”). The warrant includes a cashless exercise provision and repricing adjustments for offerings at a price lower than the existing exercise price of the warrants, stock splits, reclassifications, subdivisions, and other similar transactions (“September 2023 Warrant Adjustments”) and therefore, these warrants were recorded at their fair value as a derivative liability and the time of the grant and are revalued at the end of each reporting period. c. During the year ended October 31, 2023, the Company recorded a loss on the revaluation of the total derivative warrants liabilities of $2,189,986, in the Consolidated Statements of Operations and Comprehensive Loss. d. The binomial model was used to measure the derivative warrant liability with the following assumptions: October 31, Share Price $ 3.66-$11.52 Exercise Price $ 5.12-$23.40 Expected life 4.43-5 years Risk-free interest rate 3.37-4.95 % Dividend yield 0.00 % Expected volatility 74.79-157.7 % e. The following table presents the changes in the warrants liability during the period: Balance as of November 1, 2022 $ - Issuance of April 2023 Warrants 1,771,208 Issuance of September 2023 Warrants 923,225 Exercise of warrants (574,040 ) Changes in fair value of warrants 2,189,986 Balance as of October 31, 2023 $ 4,310,379

Share Capital

Share Capital	12 Months Ended
	Oct. 31, 2023
Share Capital [Abstract]
Share Capital	8. Share Capital a. The Company’s authorized share capital is unlimited common shares without par value share. As of October 31, 2023, the number of common shares issued and outstanding is 607,337 (October 31, 2022 – 43,992). b. On September 30, 2022 and November 28, 2023, the Company effected a 1-for-30 share consolidation (“Reverse Share Split”) of its issued and outstanding common shares. All share amounts and instruments convertible into common shares prior to the date of the reverse share split have been retroactively restated for all periods presented. c. Share transactions during the year ended October 31, 2023: (i) On November 14, 2022, the Company completed an underwritten public offering of 38,462 common shares at a price to the public of US$195.00 per share, for aggregate gross proceeds of US$7.5 million, prior to deducting underwriting discounts and offering expenses. The offering closed on November 17, 2022. Net proceeds from the offering were $6,363,906. In addition, the Company granted Aegis Capital Corp. (“Aegis”), who acted as the underwriters for the deal, a 45-day option to purchase up to 5,769 additional common shares, equal to 15% of the number of common shares sold in the offering solely to cover over-allotments, if any (“Over-Allotment”). The public purchase price per additional common share would have been $195.00 per share. The Over-Allotment was not exercised. Aegis received 1,923 underwriter warrants, each such warrant entitling the agents to receive one common share upon payment of $243.75 per share, exercisable six months after the commencement of sales of this offering and expiring on a date which is no more than five years after the commencement of sales of the offering. The fair value of the underwriter warrants of $337,579 were accounted for as an issuance cost within the share-based payment reserve. The fair value of the underwriters warrants was estimated using the Black-Scholes option pricing model assuming no expected dividends or forfeitures and the following weighted average assumptions: Risk-free interest rate 1.43 % Expected life (in years) 5 Expected volatility 150 % In connection with the offering, the Company’s common shares were approved for listing on the Nasdaq and began trading on the Nasdaq (in addition to the CSE) under the symbol “CMND” on November 15, 2022. Following the public offering and pursuant to the Medigus SPA (see note 8d(iii)), Medigus was entitled to receive 1,494 common shares and 75 warrants pursuant to an anti-dilution clause included in the agreement signed between the Company and Medigus on June 29, 2022. The anti-dilution feature was recorded as a derivative liability as of October 31, 2022. On May 23, 2023, the Company issued the 1,494 common shares and 75 warrants to Medigus. The fair value of the issuance ($296,845) was recorded in shareholder equity against the extinguishment of the derivative liability. (ii) On January 16, 2023, 161 common shares were issued in respect of RSU’s that had been fully vested. The RSU’s had a fair value of $39,975 at the time of issuance. On February 22, 2023, 400 common shares were issued in respect of fully vested RSU’s that had been fully vested. The RSU’s had a fair value of $110,096 at the time of issuance. (iii) On April 6, 2023, the Company completed an underwritten public offering of 103,249 common shares at a price to the public of US$23.40 per share and pre-funded warrants to purchase 46,942 common shares at a price to the public of US$23.37 per pre-funded warrant (“Pre-Funded Warrants”), for aggregate gross proceeds of US$3.5 million (the “April 2023 Public Offering”). The Pre-Funded Warrants were exercisable at $0.03 into one common share, and all the Pre-Funded Warrants were exercised by April 30, 2023. In addition, each April 2023 Public Offering shareholder and each Pre-Funded Warrant holder received a common warrant, which was immediately exercisable, will expire five years from the date of issuance and have an exercise price of US$23.40 per common share (“April 2023 Public Offering Warrant”). The April 2023 Public Offering warrants include a cashless exercise provision and repricing provisions under certain circumstances, that also includes a potential change in the number of shares to be issued for each warrant depending on the change in the exercise price of the warrant. On September 24, 2023, as a result of the September 2023 Public Offering, which included the offering of common shares at a price lower than the exercise price of the April 2023 Warrants, the exercise price of these warrants was reduced to $5.124, and each April 2023 Warrant is convertible into 4.6 common shares of the Company (See also note 19(b)). Net proceeds from the offering were $2,936,079. (iv) On May 23, 2023, 239 common shares with a fair value of $27,965 were issued to consultants and 1,494 common shares with a fair value of $110,000 were issued to providers of investor services in respect of services. (v) On June 1, 2023, 245 common shares were issued in respect of RSU’s that had been fully vested. The RSU’s had a fair value of $48,194 at the time of issuance. (vi) On July 10, 2023, 597 common shares with a fair value of $10,000 were issued to providers of investor services in respect of services. (vii) On August 28, 2023, 585 common shares were issued in respect of RSU’s that had been fully vested. The RSU’s had a fair value of $65,143 at the time of issuance and 44 common shares with a fair value of $607 were issued to providers of investor services in respect of services. (viii) On September 18, 2023 the Company completed an underwritten public offering of 225,833 common shares at a price to the public of US$9.00 per share and pre-funded warrants to purchase 24,167 common shares at a price to the public of US$8.97 per pre-funded warrant (“Pre-Funded Warrants”), for aggregate gross proceeds of US$2.25 million (the “September 2023 Public Offering”). The Pre-Funded Warrants were exercisable at $0.03 into one common share, and all the Pre-Funded Warrants were exercised by September 30, 2023. In addition, each September 2023 Public Offering shareholder and each Pre-Funded Warrant holder received a common warrant, which was immediately exercisable, will expire five years from the date of issuance and have an exercise price of US$9.00 per common share (“September 2023 Public Offering Warrant”). The September 2023 Public Offering warrants include a cashless exercise provision and repricing provisions under certain circumstances that also includes a potential change in the number of shares to be issued for each warrant depending on the change in the exercise price of the warrant. Net proceeds from the offering were $1,814,193 (See also note 19(b)). (ix) During the period between October 17, 2023 and October 20, 2023, 26,153 April 2023 Warrants with a fair value of $574,040 were exercised into 119,433 common shares. d. Share transactions during the year ended October 31, 2022: (i) On November 26, 2021, the Company issued 44 shares of common stock with a fair value of $21,100 to the Chief Science Officer (“CSO”) of the Company. (ii) On February 14, 2022, the Company issued 45 shares of common stock with a fair value of $17,584 to the CSO. (iii) On February 14, 2022, the Company completed a share purchase agreement with Medigus, whereby the Company issued a total of 2,208 units to Medigus in consideration for US$750,000 (“Cash Financing”) and 27,778 common shares of Medigus (“Share Exchange”). Each unit is comprised of one common share and one warrant, with each warrant exercisable for a period of 18 months at CAD$60.00 per share (the “Medigus SPA”). The Medigus SPA contains certain anti dilution provisions. Pursuant to the Cash Financing, the Company issued 1,325 units at $720.00 per unit for proceeds of $698,897. In connection with the Cash Financing, the Company incurred finder’s fees of $69,890, which have been charged to the statement of changes in equity. Pursuant to the Share Exchange, the Company issued 883 units with a fair value of $455,487, consisting of common shares with a fair value of $372,745 and warrants with a fair value of $82,742. The fair value of the warrants was determined using the Black-Scholes option pricing model with the following assumptions: Risk-free rate of 1.43%, expected life of 1.5 years, and volatility of 107.46%. In connection with the Share Exchange, the Company incurred finder’s fees of $50,000, which were allocated to the base cost of the shares in Medigus. On June 29, 2022, the Company signed an amendment to the Medigus Agreement (“Medigus Amended Agreement”), pursuant to which, in the event of an initial public offering, Medigus would receive, in respect of the Cash Financing, for no additional consideration, the number of shares necessary to maintain an ownership percentage of the Company’s shares equal to the level of ownership it had at the time of the Medigus Agreement. As of October 31, 2022, the Company recorded the fair value of this derivative financial liability in the amount of $290,569 as a current liability. e. Share transactions during the year ended October 31, 2021: (i) On April 9, 2021, the Company issued 11,111 common shares at $98.91 per share for gross proceeds of $1,098,982. In connection with this private placement, the Company paid a finder’s fee of $85,857. (ii) On June 22, 2021, the Company issued 9,222 units at $494.54 per unit for gross proceeds of $4,560,773. Each unit consisted of one common share and one share purchase warrant exercisable at $824.24 per common share expiring on December 22, 2022. In connection, with this private placement, the Company paid finders’ fees of $435,197.

Share Purchase Warrants

Share Purchase Warrants	12 Months Ended
	Oct. 31, 2023
Share Purchase Warrants [Abstract]
Share Purchase Warrants	9. Share Purchase Warrants The following table summarizes the changes in the Company’s share purchase warrants: Number of Weighted Balance, October 31, 2021 17,555 $ 482.55 Issued (i) 2,208 1,325.67 (*) Balance, October 31, 2022 19,763 576.66 Issuance of underwriter warrants (Note 8c (i)) 1,923 243.75 Issuance of April 2023 warrants (Note 7a) 150,191 (**) 5.124 Issuance of September 2023 warrants (Note 7b) 250,000 9.00 Issuance of Medigus warrants (Note 8c (i)) 75 1,297.67 (*) Expiration of warrants (11,430 ) 922.98 Exercise of warrants (Note 7a) (26,153 ) 5.124 Balance, October 31, 2023 384,369 $ 7.90 Number of shares to be issued from the exercise of warrants 826,781 (***) (*) Warrants issued with an exercise price of CAD$1,800.00. (**) These warrants convert into 685,883 shares. (***) See note 19(b). (i) On February 14, 2022, the Company completed the Medigus Agreement, whereby the Company completed the Cash Financing and the Share Exchange. Each unit was comprised of one common share and one warrant, with each warrant exercisable at $1,297.67 per common share for a period of 18 months. As of October 31, 2023, the following share purchase warrants were outstanding: Number of Number of shares Exercise price Exercise price (USD) Expiry date 8,333 8,333 C$ 135.00 $ 97.33 April 22, 2024 1,923 1,923 $ 243.75 $ 243.75 November 17, 2027 124,038 566,450 $ 5.124 $ 5.124 April 6, 2028 75 75 C$ 1,800 $ 1,297.67 November 23, 2024 250,000 250,000 $ 9.00 $ 9.00 September 17, 2028 384,369 826,781 (*) (*) See note 19(b).

Stock Options

Stock Options	12 Months Ended
	Oct. 31, 2023
Notes and other explanatory information [abstract]
Stock Options	10. Stock Options a. On September 1, 2021, the Company implemented a stock option plan pursuant to which stock options may be granted to directors, officers, employees, and consultants of the Company. The Board is authorized to grant the maximum number of common shares reserved for issuance in any 12-month period to anyone, optionee, other than a consultant may not exceed 5% of the issued and outstanding common shares at the date of the grant. The maximum number of common shares reserved for issuance in any 12-month period to any consultant may not exceed 2% of the issued and outstanding common shares at the date of the grant and the maximum number of common shares reserved for issuance in any 12-month period to all persons engaged in investor relations activities may not exceed 2% of the issued and outstanding number of common shares at the date of the grant. See also note 19(e). b. The following table summarizes the changes in the Company’s stock options for the years ended October 31, 2023 and October 31, 2022: Number of Weighted (C$) Weighted (USD$) Outstanding, October 31, 2021 3,729 C$ 620.10 $ 455.49 Granted (i) 2,877 620.40 455.71 Cancelled (ii) (1,352 ) 646.80 475.10 Outstanding, October 31, 2022 5,254 C$ 613.5 $ 450.64 Granted (iii, iv, v) 334 442.22 318.81 Outstanding, October 31, 2023 5,588 C$ 603.12 $ 434.81 Exercisable, October 31, 2023 4,039 C$ 606.00 $ 436.89 i) During the year ended October 31, 2022, the Company granted 2,877 stock options to officers, directors and consultants with weighted average exercise price of $455.71 per Common Share. The options vest over 3 years with expiration dates between 5 to 10 years. ii) On July 2, 2022, 222 options canceled with a fair value of $17,649. On May 7, 2022, 1,111 options canceled with a fair value of $92,170. On May 1, 2022 ,19 options canceled with a fair value of $3,959. iii) On May 23, 2023, the Company granted 61 stock options to a consultant of the Company. The options are exercisable at CAD$315.00 (USD$227.09) per share. The options expire on May 23, 2033. iv) On June 26, 2023, the Company granted 223 stock options to a consultant of the Company. The 156 options are exercisable at CAD$504 (USD$363.35) per share and the 67 options are exercisable at CAD$720.00 (USD$519.07) per share. The options expire on June 26, 2033. v) On July 6, 2023, the Company granted 50 stock options to a consultant of the Company. The options are exercisable at $23.40 per share. The options expire on July 6, 2033. c. Additional information regarding stock options outstanding as of October 31, 2023, is as follows: Outstanding Exercisable Number of Weighted Weighted Weighted Number of Weighted Weighted 533 2.57 C$ 166.50 $ 120.03 400 C$ 166.50 $ 120.03 978 8.26 504.00 363.35 667 504.00 363.35 1,166 2.57 675.00 486.63 916 675.00 486.63 200 5.50 702.00 506.09 142 702.00 506.09 133 2.89 747.00 538.53 133 747.00 538.53 422 8.11 612.00 441.21 422 612.00 441.21 1,044 8.26 720.00 519.07 609 720.00 519.07 667 2.67 756.00 545.02 500 756.00 545.02 111 8.11 900.00 648.84 74 900.00 648.84 61 9.57 315.00 227.09 31 315.00 227.09 67 9.66 720.00 519.07 33 720.00 519.07 156 9.66 504.00 363.35 104 504.00 363.35 50 9.69 32.46 23.40 8 32.46 23.40 5,588 5.70 C$ 603.12 $ 434.81 4,039 C$ 606.00 $ 436.89 The fair value of stock options previously granted to certain consultants for ongoing services measured during the period have been estimated using the Black-Scholes option pricing model assuming no expected dividends or forfeitures and the following weighted average assumptions: Year ended October 31, 2023 2022 Risk-free interest rate 4.10 % 2.05 % Expected life (in years) 5.61 8.67 Expected volatility 140.41-160.81 % 94.09 % d. The portion of the total fair value of stock options expensed during the year ended October 31, 2023, was $221,625 (2022 - $788,657) which was recorded as share-based compensation expense.

Restricted Share Units

Restricted Share Units	12 Months Ended
	Oct. 31, 2023
Restricted Share Units [Abstract]
Restricted Share Units	11. Restricted Share Units a. On August 4, 2021, the Company approved an RSU plan, which is designed to provide certain directors, officers, employees, and consultants of the Company with the opportunity to acquire RSU’s of the Company. Each unit is equivalent in value to a common share and upon vesting results in the holder thereof being issued, at the discretion of the Board, either (i) a common share, or (ii) an amount of cash equal to the fair market value of a common share. b. The following table summarizes the changes in RSUs: Number of Weighted Weighted Balance, October 31, 2021 – $ – $ – Granted 1,177 316.50 232.48 Vested (1,177 ) 316.50 232.48 Balance, October 31, 2022 – $ – $ – Granted (i) 2,200 55.97 41.46 Vested (2,200 ) 55.97 41.46 Balance, October 31, 2023 – $ – $ – (i) During the year ended October 31, 2023, the Company issued 2,200 RSU’s with a fair value of $91,589 to consultants (2022 - $272,985). c. During the year ended October 31, 2023, the Company recognized share-based compensation of $( 171,819 380 207

Financial Instruments and Risk

Financial Instruments and Risk Management	12 Months Ended
	Oct. 31, 2023
Financial Instruments and Risk Management [Abstract]
Financial Instruments and Risk Management	12. Financial Instruments and Risk Management a. Fair Values Fair value measurements are classified using a fair value hierarchy that reflects the significance of inputs used in making the measurements. The fair value hierarchy has the following levels: ● Level 1 - valuation based on quoted prices (unadjusted) in active markets for identical assets or liabilities; ● Level 2 - valuation techniques based on inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices); and ● Level 3 - valuation techniques using inputs for the asset or liability that are not based on observable market data (unobservable inputs). Assets and liabilities measured at fair value on a recurring basis were presented on the Company’s statement of financial position as of October 31, 2023, as follows: Fair Value Measurements Using Quoted prices Significant Significant Balance Short-term investment $ 86,112 $ – $ – $ 86,112 Derivative warrants liability – – 4,310,379 4,310,379 Assets and liabilities measured at fair value on a recurring basis were presented on the Company’s statement of financial position as of October 31, 2022, as follows: Fair Value Measurements Using Quoted prices Significant Significant Balance Short-term investment $ 193,750 $ – $ – $ 193,750 Derivative liability – 290,569 – 290,569 The fair value of other assets and liabilities, which include cash and cash equivalents, amounts receivable, accounts payable and accrued liabilities, and amounts due to / from related parties, approximate their carrying values due to the relatively short-term maturity of these instruments. b. Credit Risk Financial instruments that potentially subject the Company to a concentration of credit risk consist primarily of cash and cash equivalents. The Company limits its exposure to credit loss by placing its cash with high credit quality financial institutions. The carrying amount of financial assets represents the maximum credit exposure. c. Foreign Exchange Rate Risk Foreign currency risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate due to changes in foreign exchange rates. The Company is exposed to foreign currency risk to the extent that monetary assets and liabilities are denominated in a foreign currency. The Company’s subsidiary operates in Israel and has certain monetary financial instruments denominated in NIS and CAD. The Company has not entered into foreign exchange rate contracts to mitigate this risk. The following table indicates the impact of foreign currency exchange risk on net working capital as of October 31, 2023. The table below also provides a sensitivity analysis of a 10% strengthening of the foreign currency against functional currencies identified which would have increased (decreased) the Company’s net loss by the amounts shown in the table below. A 10% weakening of the foreign currency against the functional currencies would have had the equal but opposite effect as of October 31, 2023. Cash $ 78,503 Amounts receivable 104,320 Accounts payable and accrued liabilities (177,226 ) Due to related parties (42,433 ) Total foreign currency financial assets and liabilities $ (36,836 ) Impact of a 10% strengthening or weakening of foreign exchange rate $ (3,684 ) d. Interest Rate Risk Interest rate risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The fair value of the warrant liability can fluctuate depending on the fluctuation in the risk free interest rate. e. Liquidity Risk Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due. The Company’s objective to managing liquidity risk is to ensure that it has sufficient liquidity available to meet its liabilities when due. The Company relies on raising debt or equity financing in a timely manner. The following amounts are the contractual maturities of financial liabilities as of October 31, 2023 and 2022: October 31, 2023 Total Within Within Accounts payable and accrued liabilities $ 617,004 $ 617,004 $ – Due to related parties 42,433 42,433 – $ 659,437 $ 659,437 $ – October 31, 2022 Total Within Within Accounts payable and accrued liabilities $ 1,396,960 $ 1,396,960 $ – Due to related parties 206,494 206,494 – Lease liability 38,390 38,390 – $ 1,641,844 $ 1,641,844 $ –

Capital Management

Capital Management	12 Months Ended
	Oct. 31, 2023
Capital Management [Abstract]
Capital Management	13. Capital Management The Company manages its capital to maintain its ability to continue as a going concern and to provide returns to shareholders and benefits to other stakeholders. The capital structure of the Company consists of cash and equity comprised of issued share capital and share premium, warrants and share-based payment reserve. The Company manages its capital structure and makes adjustments to it in light of economic conditions. The Company, upon approval from its Board, will balance its overall capital structure through new share issuances or by undertaking other activities as deemed appropriate under the specific circumstances. The Company is not subject to externally imposed capital requirements and the Company’s overall strategy with respect to capital risk management remains unchanged from the year ended October 31, 2022.

Commitments

Commitments	12 Months Ended
	Oct. 31, 2023
Commitments [Abstract]
Commitments	14. Commitments The Company enters into contracts in the ordinary course of business with contract research organizations for clinical trials and clinical supply manufacturing and with vendors for non-clinical research studies and other services and products for operating purposes, which generally provide for termination upon 30 to 120 days’ notice or less, and therefore are cancelable contracts and not considered as commitment or purchase obligations.

Segmented Information

Segmented Information	12 Months Ended
	Oct. 31, 2023
Notes and other explanatory information [abstract]
Segmented Information	15. Segmented Information As of October 31, 2023, the Company has one operating segment, research and development of psychedelic medicine, which takes place primarily in Israel.

Income Taxes

Income Taxes	12 Months Ended
	Oct. 31, 2023
Income Taxes [abstract]
Income Taxes	16. Income Taxes Tax rates applicable to the Company: The combined Canadian federal and provincial statutory income tax rate is 27% for years ended October 31, 2023, 2022 and 2021 and the Israeli statutory corporate tax rate was 23% in 2023, 2022 and 2021. The tax effect (computed by applying the Canadian federal and provincial statutory rate) of the significant differences, which comprise deferred income tax assets and liabilities, are as follows: 2023 2022 2021 Canadian statutory income tax rate 27 % 27 % 27 % Income tax recovery at statutory rate (2,322,936 ) (1,861,476 ) (771,373 ) Tax effect of: Permanent differences and other 204,134 335,494 (3,255 ) Tax rate difference for foreign jurisdiction 10,715 56,175 40,185 Change in unrecognized deferred income tax assets 2,125,459 1,499,666 734,443 Income tax provision 17,372 29,859 - As of October 31, 2023, the Company has Canadian non-capital losses carried forward of $13,176,000, which is available to offset future years’ taxable income in Canada. These losses expire as follows: $ 2037 4,085 2038 75,465 2039 73,535 2040 175,671 2041 1,183,266 2042 4,887,566 2043 6,775,908 13,176,216 As of October 31, 2023, the Company has a non-capital loss carried forward of approximately $2,253,000 which is available to offset future years’ taxable income in Israel. Deferred tax assets have not been recognized in respect of these items because it is not probable that future taxable profit will be available against which the Company can utilize the benefits therefrom.

General and Administrative Expe

General and Administrative Expenses	12 Months Ended
	Oct. 31, 2023
General and Administrative Expenses [Abstract]
General and Administrative Expenses	17. General and Administrative Expenses Year ended Year ended Year ended October 31, October 31, October 31, 2023 2022 2021 Professional fees $ 2,210,795 $ 1,093,871 $ 480,630 Investor relations 1,565,970 473,106 114,706 Share-based compensation (Notes 6, 10 and 11) 243,717 946,324 619,939 Consulting fees (Note 6) 96,421 192,448 521,739 Insurance 364,059 149,537 103,096 Transfer agent and regulatory fees 171,439 86,605 42,492 Depreciation of ROU asset 35,381 60,665 - Salaries and benefits (Note 6) 37,838 92,296 297,188 Office and miscellaneous 31,670 68,016 38,069 Depreciation of property and equipment 1,915 7,572 1,886 Total general and administrative $ 4,759,205 $ 3,170,440 $ 2,219,745

Research and Development

Research and Development	12 Months Ended
	Oct. 31, 2023
Research and Development [Abstract]
Research and Development	18. Research and Development, net Year ended Year ended Year ended October 31, October 31, October 31, 2023 2022 2021 Research and preclinical studies $ 1,159,147 $ 2,380,942 $ - Salaries, regulatory, professional and other expenses 469,667 666,125 473,652 Share-based compensation (Notes 6, 10 and 11) 45,870 213,299 - Reimbursements (Note 6) (141,409 ) (194,205 ) - Amortization of intangible assets 10,954 14,830 - Total research and development, net $ 1,544,229 $ 3,080,991 $ 473,652

Subsequent Events

Subsequent Events	12 Months Ended
	Oct. 31, 2023
Subsequent Events [Abstract]
Subsequent Events	19. Subsequent Events a. Reverse share split – see note 1(c). b. Warrant exercises As a result of the Reverse Share Split, on November 28, 2023, pursuant to the April 2023 Warrant Adjustments and September 2023 Warrant Adjustments, the exercise price of the April 2023 Warrants and September 2023 Warrants was adjusted to $3.181 and the April 2023 Warrant and September 2023 Warrant is convertible into a total 1,619,768 common shares of the Company. Between November 30, 2023 and December 4, 2023, April 2023 Warrants and September 2023 Warrants were exercise into 840,511 shares, resulting in gross proceeds of $2,673,665. On December 5, 2023, the exercise price of the April 2023 Warrants and September 2023 Warrants was further adjusted to $3.6223 such that the April 2023 Warrant and September 2023 Warrant is convertible into a total of 684,315 common shares of the Company. On December 5, 2023, April 2023 Warrants and September 2023 Warrants were exercised into 221,677 shares, resulting in gross proceeds of $802,981. On January 21, 2024, following a registered direct and private placement (See below), the April 2023 Warrants and September 2023 Warrant exercise prices were further adjusted to $1.0777 and are convertible into a total of 1,554,991 common shares of the Company. c. New lease agreement – see note 4. d. Registered direct and private placement On January 16, 2024, the Company completed a registered direct and private placement (the “January 2024 Offering”) of 1,468,00 e. Omnibus Equity Inventive Plan On November 14, 2023, the shareholders of the Company approved the Omnibus Equity Incentive Plan, or the Omnibus Plan. Pursuant to the Omnibus Plan, the Company is authorized to grant options or restricted share units (“RSUs” and together with “Options”, “Awards” or “Stock Awards”) to officers, directors, employees and consultants enabling them to acquire up to 20% of our issued and outstanding Common Shares. The Awards can be granted for a maximum of 10 years and vest as determined by the Board.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	12 Months Ended
	Oct. 31, 2023
Accounting Policies [Abstract]
Basis of Presentation	a. Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (“IFRS”), as issued by the International Accounting Standards Board (“IASB”) on a going concern basis. These consolidated financial statements include the accounts of the Company and its 100% owned subsidiaries, Clearmindmed Ltd. and Clearmind Labs Corp. (inactive). All inter-company balances and transactions have been eliminated on consolidation. These consolidated financial statements have been prepared on a historical cost basis, except for financial assets and liabilities (including derivatives) which are presented at fair value through profit or loss (“FVTPL”), and are presented in United States dollars, which is the Company’s functional currency as of November 1, 2022.
Significant Accounting Estimates and Judgments	b. Significant Accounting Estimates and Judgments The preparation of consolidated financial statements in accordance with IFRS requires management to make judgments, estimates, and assumptions that affect the application of policies and reported amounts of assets, liabilities, income, and expenses. The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making the judgments about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates. Significant Estimates Share-based Compensation Fair values are determined using the Black-Scholes option pricing model. Estimating fair value requires determining the most appropriate valuation model for a grant of equity instruments, which is dependent on the terms and conditions of the grant. Option-pricing models require the use of highly subjective estimates and assumptions including the expected stock price volatility. Changes in the underlying assumptions can materially affect the fair value estimates and, therefore, existing models do not necessarily provide reliable measurement of the fair value of the Company’s stock options. Warrant Liability The Company analyses warrants issued to determine whether they meet the classification as liabilities or equity. Derivative warrant liabilities are adjusted to reflect fair value at each reporting period, with any increase or decrease in the fair value recorded in the results of operations. The Company uses a fair valuation specialist to estimate the value of these instruments using the Black and Scholes and binomial pricing model. The key assumptions used in the models are the expected future volatility in the price of the Company's shares, the expected life of the warrants and the probability of any future adjustment event. Significant Judgments The critical judgments that the Company’s management has made in the process of applying the Company’s accounting policies that have the most significant effect on the amounts recognized in the Company’s consolidated financial statements are as follows: Going Concern The application of the going concern assumption requires management to take into account all available information about the future, which is at least but not limited to, 12 months from the year end of the reporting period. The Company is aware that material uncertainties related to events or conditions raise substantial doubt upon the Company’s ability to continue as a going concern.
Cash and Cash Equivalents	c. Cash and Cash Equivalents The Company considers all highly liquid instruments with a maturity of three months or less at the time of issuance, which are readily convertible to known amounts of cash, and which are subject to insignificant risk of changes in value to be cash equivalents.
Provisions	d. Provisions Provisions are recognized where a legal or constructive obligation has been incurred as a result of past events; it is probable that an outflow of resources embodying economic benefit will be required to settle the obligation; and a reliable estimate of the amount of the obligation can be made. Provisions are measured at the present value of the expenditures expected to be required to settle the obligation.
Property and Equipment	e. Property and Equipment Property and equipment are stated at cost less accumulated depreciation and accumulated impairment losses. Cost includes expenditures that are directly attributable to the acquisition of the asset. Subsequent costs are included in the asset’s carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Company and the cost can be measured reliably. The carrying amount of a replaced asset is derecognized when replaced. Repairs and maintenance costs are charged to the consolidated statements of operations and comprehensive loss during the period in which they are incurred. Depreciation of property and equipment is provided using the straight-line method at the following rates approximating their estimated useful lives: Research and development equipment 3 years Computer equipment 3 years
Intangible Assets	f. Intangible Assets Intangible assets consist of patents and patent applications acquired to be used in drug research programs. Intangible assets are carried at cost less accumulated amortization and impairment losses and are capitalized when the costs can be measured reliably, and it is probable that future economic reliably benefits that are attributable to the asset will flow to the Company. The Company amortizes patents over the term of the patent.
Impairment of Non-Current Assets	g. Impairment of Non-Current Assets At each reporting date, the Company reviews the carrying amounts of its non-current assets to determine whether there are any indications of impairment. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment, if any. Where the asset does not generate cash flows that are independent from other assets, the Company estimates the recoverable amount of the cash generating unit (“CGU”) to which the asset belongs. The recoverable amount is determined as the higher of fair value less direct costs to sell and the asset’s value in use. In assessing value in use, the estimated future cash flows are discounted to their present value. Estimated future cash flows are calculated using estimated recoverable reserves, estimated future commodity prices and the expected future operating and capital costs. The pre-tax discount rate applied to the estimated future cash flows reflects current market assessments of the time value of money and the risks specific to the asset for which the future cash flow estimates have not been adjusted. If the carrying amount of an asset or CGU exceeds its recoverable amount, the carrying amount of the asset or CGU is reduced to its recoverable amount through an impairment charge to the consolidated statement of operations and comprehensive loss. Assets that have been impaired are tested for possible reversal of the impairment whenever events or changes in circumstance indicate that the impairment may have reversed. When an impairment subsequently reverses, the carrying amount of the asset or CGU is increased to the revised estimate of its recoverable amount, but only so that the increased carrying amount does not exceed the carrying amount that would have been determined (net of depreciation, depletion and amortization) had no impairment loss been recognized for the asset or CGU in prior periods. A reversal of impairment is recognized as a gain in the consolidated statement of operations and comprehensive loss.
Financial Instruments	h. Financial Instruments Financial assets and financial liabilities are recognized when the Company becomes a party to the contractual provisions of the respective instrument. Financial assets and financial liabilities are initially measured at fair value. Transaction costs that are directly attributable to the acquisition or issuance of financial assets and financial liabilities (other than financial assets and financial liabilities at FVTPL) are included in the initial carrying value of the related instrument and are amortized using the effective interest method. Transaction costs directly attributable to the acquisition of financial assets or financial liabilities at FVTPL are recognized immediately in the consolidated statement of operations and comprehensive loss. Financial assets The classification of financial assets depends on the nature and purpose of the financial assets and is determined at the time of initial recognition. Financial assets at FVTPL Financial assets are classified as FVTPL when the financial asset is either held for trading or it is designated as FVTPL. A financial asset is classified as held for trading if: ● it has been acquired principally for the purpose of selling it in the near term; or ● on initial recognition it is part of a portfolio of identified financial instruments that the Company manages together and has a recent actual pattern of short-term profit-taking. Financial assets at amortized cost Financial assets at amortized cost are non-derivative financial assets which are held within a business model whose objective is to hold assets to collect contractual cash flows and its contractual terms give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. A financial asset (unless it is a trade receivable without a significant financing component that is initially measured at the transaction price) is initially measured at fair value plus, for an item not at FVTPL, transaction costs that are directly attributable to its acquisition. Subsequent to initial recognition, financial assets are measured at amortized cost using the effective interest method, less any impairment. Financial liabilities and equity instruments Classification as debt or equity Debt and equity instruments issued by the Company are classified as either financial liabilities or as equity in accordance with the substance of the contractual arrangements and the definitions of a financial liability and an equity instrument. Equity instruments An equity instrument is any contract that evidences a residual interest in the assets of an entity after deducting all of its liabilities. Equity instruments issued by the Company are recognized as the proceeds received, net of direct issue costs. Other financial liabilities All financial liabilities are measured subsequently at amortized cost using the effective interest method or at FVTPL. Financial liabilities at FVTPL Financial liabilities are classified as at FVTPL when the financial liability is (i) contingent consideration of an acquirer in a business combination, (ii) held for trading or (iii) it is designated as at FVTPL. A financial liability is classified as held for trading if either: ● It has been acquired principally for the purpose of repurchasing it in the near term ● On initial recognition it is part of a portfolio of identified financial instruments that the group manages together and has a recent actual pattern of short-term profit-taking ● It is a derivative, except for a derivative that is a financial guarantee contract or a designated and effective hedging instrument Financial liabilities at FVTPL are measured at fair value, with any gains or losses arising on changes in fair value recognized in profit or loss. Financial liabilities measured subsequently at amortized cost Financial liabilities that are not (i) contingent consideration of an acquirer in a business combination, (ii) held-for-trading, or (iii) designated as at FVTPL, are measured subsequently at amortized cost using the effective interest method. The effective interest method is a method of calculating the amortised cost of a financial liability and of allocating interest expense over the relevant period. The effective interest rate is the rate that exactly discounts estimated future cash payments (including all fees and points paid or received that form an integral part of the effective interest rate, transaction costs and other premiums or discounts) through the expected life of the financial liability, or (where appropriate) a shorter period, to the amortised cost of a financial liability.
Income Taxes	i. Income Taxes Current income tax The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in profit or loss because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The Company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period. Deferred income tax Deferred income tax is provided using the statement of financial position method on temporary differences at the reporting date between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes. The carrying amount of deferred income tax assets is reviewed at the end of each reporting period and recognized only to the extent that it is probable that sufficient taxable income will be available to allow all or part of the deferred income tax asset to be utilized. Deferred income tax assets and liabilities are measured at the tax rates that are expected to apply to the year when the asset is realized or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period. Deferred income tax assets and deferred income tax liabilities are offset, if a legally enforceable right exists to set off current tax assets against current income tax liabilities and the deferred income taxes relate to the same taxable entity and the same taxation authority.
Foreign Currency Translation	j. Foreign Currency Translation The Company’s reporting currency is the United States dollar. The functional currency for the Company and its subsidiary is the currency of the primary economic environment in which the entity operates. As of November 1, 2023, the functional currency of the Company and its Canadian and Israeli subsidiaries is the United States dollar. Transactions denominated in currencies other than the functional currency are translated using the exchange rate in effect on the transaction date or at the annual average rate. Monetary assets and liabilities denominated in foreign currencies are retranslated at the rate of exchange in effect at the consolidated statement of financial position date. Non-monetary items are translated using the historical rate on the date of the transaction. Foreign exchange gains and losses are included in the consolidated statement of operations and comprehensive loss.
Share-based Payments	k. Share-based Payments The grant date fair value of share-based payment awards granted to employees is recognized as stock-based compensation expense, with a corresponding increase in equity, over the period that the employees unconditionally become entitled to the awards. The amount recognized as an expense is adjusted to reflect the number of awards for which the related service and non-market vesting conditions are expected to be met, such that the amount ultimately recognized as an expense is based on the number of awards that do meet the related service and non-market performance conditions at the vesting date. For share-based payment awards with non-vesting conditions, the grant date fair value of the share-based payment is measured to reflect such conditions and there is no true-up for differences between expected and actual outcomes. Where equity instruments are granted to parties other than employees, they are recorded by reference to the fair value of the services received. If the fair value of the services received cannot be reliably estimated, the Company measures the services received by reference to the fair value of the equity instruments granted, measured at the date the counterparty renders service. The fair value of services received from consultants cannot be reliably measured; therefore, the fair value of the underlying equity instruments was utilized for all periods presented. All equity-settled share-based payments are reflected in share-based payment reserve, unless exercised. Upon exercise, shares are issued and the amount reflected in share-based payment reserve is credited to share capital, adjusted for any consideration paid.
Restricted Share Units	l. Restricted Share Units The Company recognizes compensation expense for restricted share units (“RSU’s”) awarded based on the grant-date fair value of the common shares. The grant-date fair value, which is determined by multiplying the Company’s share price by the number of RSU’s granted, is amortized over the vesting period and is included in compensation expense with a corresponding increase in the share-based payment reserve. If RSU’s are for services that have been provided and are non-cancellable, the Company recognizes the full cost of the RSU’s on the date of grant. The amount recognized is adjusted to reflect the number of RSU’s expected to eventually vest.
Leases	m. Leases The Company’s Israeli subsidiary leased an office through to June 30, 2023. At inception of a contract, the Company assesses whether a contract is, or contains, a lease. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. The Company reassesses whether a contract is, or contains, a lease only if the terms and conditions of the contract are changed. At the commencement date, the Company measures the lease liability at the present value of the lease payments that are not paid at that date, including, inter alia, the exercise price of a purchase option if the Company is reasonably certain to exercise that option. Simultaneously, the Company recognizes a right-of-use (“ROU”) asset in the amount of the lease liability. The discount rate applied by the Company is the rate of interest that the Company would have to pay to borrow over a similar term, and with a similar security, the funds necessary to obtain an asset of a similar value to the ROU asset in a similar economic environment. The weighted average of lessee’s incremental annual borrowing rate applied to the lease liabilities as of June 30, 2023 was estimated at 20%. The lease term is the non-cancellable period for which the Company has the right to use an underlying asset, together with both, the periods covered by an option to extend the lease if the Company is reasonably certain to exercise that option and periods covered by an option to terminate the lease if the Company is reasonably certain not to exercise that option. After the commencement date, the Company measures the ROU asset applying the cost model, less any accumulated depreciation and any accumulated impairment losses and adjusted for any remeasurement of the lease liability. Assets are depreciated by the straight-line method over the estimated useful lives of the ROU asset or the lease period, whichever is shorter. Interest on the lease liability is recognized in profit or loss in each period during the lease term in an amount that produces a constant periodic rate of interest on the remaining balance of the lease liability. The Company applied the following practical expedients: ● Non-lease components: practical expedient by class of underlying asset not to separate non-lease components (services) from lease components and, instead, account for each lease component and any associated non lease components as a single lease component. ● The practical expedient for short-term leases is applied.
Employee benefits	n. Employee benefits 1) Pension and retirement benefit obligations The Company operates a number of post-employment defined contribution plans. A defined contribution plan is a program that benefits an employee after termination of employment, under which the Company regularly makes fixed payments to a separate and independent entity so that the Company has no legal or constructive obligation to pay additional contributions if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods. The fund assets are not included in the Company’s statement of financial position. The Company operates pension and severance compensation plans subject to Section 14 of the Israeli Severance Pay Law. The Option Plans are funded through payments to insurance companies or pension funds administered by trustees. In accordance with its terms, the Option Plans meet the definition of a defined contribution plans as defined above. The expenses in respect of defined contribution plans during the years ended October 31, 2023, 2022 and 2021 were $13,988, $31,157 and $50,661, respectively. 2) Vacation and recreation pay Under Israeli law, each employee is entitled to vacation days and recreation pay, both computed on an annual basis. The entitlement is based on the period of employment. The Company records a liability and an expense for vacation and recreation pay, based on the benefit accumulated for each employee.
Research and Development	o. Research and Development Research costs are charged to operations as incurred. Development activities involve a plan or design for the production of new or substantially improved products and processes. Development expenditures are capitalized only if development costs can be measured reliably, the product is technically and commercially feasible, future economic benefits are probable, and the Company intends to or has sufficient resources to complete development and to use or sell the asset. The expenditure capitalized includes the cost of materials, direct labor and overhead costs that are directly attributable to preparing the asset for its intended use and borrowing costs on qualifying assets. Other development expenditures are recognized in the consolidated statement of operations and comprehensive loss as incurred. The Company has not capitalized any development costs for the years ended October 31, 2023, 2022 and 2021.
Loss Per Share	p. Loss Per Share Basic loss per share is computed using the weighted average number of common shares outstanding during the period. The treasury stock method is used for the calculation of diluted loss per share, whereby all “in the money” stock options and share purchase warrants are assumed to have been exercised at the beginning of the period and the proceeds from their exercise are assumed to have been used to purchase common shares at the average market price during the period. When a loss is incurred during the period, basic and diluted loss per share is the same as the exercise of stock options and share purchase warrants is considered to be anti-dilutive. As of October 31, 2023, the Company had 833,810 (2022 – 26,419, 2021- 21,507) potentially dilutive shares outstanding.
Deferred offering costs	q. The Company capitalizes certain legal and other third-party fees that are directly related to the Company’s in- process equity financing until such financing is consummated. After consummation of such equity financing, these costs are recorded as a reduction of the respective gross proceeds. Should a planned equity financing be abandoned, terminated or significantly delayed, the deferred offering costs are written off to operating expenses. Where the financing includes both an equity and liability component, pro-rata issuance costs relating to the liability component are charged to the statement of operations.
Accounting Standards Issued But Not Yet Effective	r. Accounting Standards Issued But Not Yet Effective i) Amendments to IAS 1 Presentation of Financial Statements— The IASB issued a narrow-scope amendment to IAS 1, in January 2020, to clarify that liabilities are classified as either current or non-current, depending on the rights that exist at the end of the reporting period. The amendment could affect the classification of liabilities, particularly for entities that previously considered management’s intentions to determine classification and for some liabilities that can be converted into equity. Inter alia, the amendment requires the following: Liabilities are classified as non-current if the entity has a substantive right to defer settlement for at least 12 months at the end of the reporting period. The amendment no longer refers to unconditional rights. The assessment determines whether a right exists, but it does not consider whether the entity will exercise the right. ’Settlement’ is defined as the extinguishment of a liability with cash, other economic resources or an entity’s own equity instruments. There is an exception for convertible instruments that might be converted into equity, but only for those instruments where the conversion option is classified as an equity instrument as a separate component of a compound financial instrument. The amendments are applied retrospectively for annual periods beginning on or after 1 January 2024, with early application permitted. ii) Amendments to IAS 1 Presentation of Financial Statements and IFRS Practice Statement 2 Making Materiality Judgements - Disclosure of Accounting Policies The amendments change the requirements in IAS 1 with regard to disclosure of accounting policies. The amendments replace all instances of the term ‘significant accounting policies’ with ‘material accounting policy information’. Accounting policy information is material if, when considered together with other information included in an entity’s financial statements, it can reasonably be expected to influence decisions that the primary users of general-purpose financial statements make on the basis of those financial statements. The supporting paragraphs in IAS 1 are also amended to clarify that accounting policy information that relates to immaterial transactions, other events or conditions is immaterial and need not be disclosed. Accounting policy information may be material because of the nature of the related transactions, other events or conditions, even if the amounts are immaterial. However, not all accounting policy information relating to material transactions, other events or conditions is itself material. The IASB has also developed guidance and examples to explain and demonstrate the application of the ‘four-step materiality process’ described in IFRS Practice Statement 2. The amendments are applied for annual periods beginning on or after January 1, 2023.

Significant Accounting Polici_2

Significant Accounting Policies (Tables)	12 Months Ended
	Oct. 31, 2023
Significant Accounting Policies [Abstract]
Schedule of Property and Equipment Estimated Useful Lives	Depreciation of property and equipment is provided using the straight-line method at the following rates approximating their estimated useful lives: Research and development equipment 3 years Computer equipment 3 years

Leases (Tables)

Leases (Tables)	12 Months Ended
	Oct. 31, 2023
Leases [Abstract]
Schedule of ROU office space	ROU Balance, October 31, 2022 $ 35,730 Addition - Accumulated depreciation (35,381 ) Foreign currency fluctuation (349 ) Balance, October 31, 2023 $ -
Schedule of Lease Liability	Lease Balance, October 31, 2022 $ 38,390 Addition - Lease payments (40,922 ) Interest expense 2,907 Foreign currency translation (375 ) Balance, October 31, 2023 $ -
Schedule of Amounts Recognized in Profit or Loss	Year ended October 31, 2023 Depreciation $ 35,381 Interest 2,907 Foreign currency fluctuation 722 $ 39,010

Short-term Investment (Tables)

Short-term Investment (Tables)	12 Months Ended
	Oct. 31, 2023
Short-term Investment [Abstract]
Schedule of Fair Value of Common Shares	As of October 31, 2023, the Company holds 27,778 ordinary shares of Medigus (approximately 0.11%) with a total fair value of $86,112. The fair value of ordinary shares held was determined by reference to public price quotations in an active market. See Note 12. October 31, Additions Unrealized October 31, Medigus Ltd. – Shares $ 193,750 $ - $ (107,638 ) $ 86,112 October 31, Additions Unrealized October 31, Medigus Ltd. – Shares $ - $ 501,938 $ (308,188 ) $ 193,750

Related Party Transactions (Tab

Related Party Transactions (Tables)	12 Months Ended
	Oct. 31, 2023
Related Party Transactions [Abstract]
Schedule of Key Management Personnel for Employment Services	The compensation to key management personnel for employment services they provide to the Company is as follows: Year ended Year ended Year ended October 31, October 31, October 31, 2023 2022 2021 Officers: Payroll and other short-term benefits $ - $ 32,533 $ 297,188 Consulting fees 410,066 453,519 49,820 Share based compensation 124,808 772,786 179,996 $ 534,874 $ 1,258,838 $ 527,004 Directors: Directors’ fees $ 182,261 $ 124,746 $ 38,098 Share based compensation 121,981 43,485 17,218 $ 304,242 $ 168,231 $ 55,316
Schedule of Balances with Related Parties	Balances with related parties October 31, October 31, 2023 2022 Amounts owed to officers $ 29,666 $ 136,149 Amounts owed to directors 12,767 70,345 $ 42,433 $ 206,494

Derivative Warrants Liabiliti_2

Derivative Warrants Liabilities (Tables)	12 Months Ended
	Oct. 31, 2023
Derivative Warrants Liability Abstract
Schedule of Binomial Model was Used to Measure the Derivative Warrant Liability	The binomial model was used to measure the derivative warrant liability with the following assumptions: October 31, Share Price $ 3.66-$11.52 Exercise Price $ 5.12-$23.40 Expected life 4.43-5 years Risk-free interest rate 3.37-4.95 % Dividend yield 0.00 % Expected volatility 74.79-157.7 %
Schedule of Changes in the Warrants Liability	The following table presents the changes in the warrants liability during the period: Balance as of November 1, 2022 $ - Issuance of April 2023 Warrants 1,771,208 Issuance of September 2023 Warrants 923,225 Exercise of warrants (574,040 ) Changes in fair value of warrants 2,189,986 Balance as of October 31, 2023 $ 4,310,379

Share Capital (Tables)

Share Capital (Tables)	12 Months Ended
	Oct. 31, 2023
Share Capital [Abstract]
Schedule of the Fair Value has been Estimated using the Black-Scholes	The fair value of the underwriters warrants was estimated using the Black-Scholes option pricing model assuming no expected dividends or forfeitures and the following weighted average assumptions: Risk-free interest rate 1.43 % Expected life (in years) 5 Expected volatility 150 %

Share Purchase Warrants (Tables

Share Purchase Warrants (Tables)	12 Months Ended
	Oct. 31, 2023
Share Purchase Warrants [Abstract]
Schedule of Share Purchase Warrants	The following table summarizes the changes in the Company’s share purchase warrants: Number of Weighted Balance, October 31, 2021 17,555 $ 482.55 Issued (i) 2,208 1,325.67 (*) Balance, October 31, 2022 19,763 576.66 Issuance of underwriter warrants (Note 8c (i)) 1,923 243.75 Issuance of April 2023 warrants (Note 7a) 150,191 (**) 5.124 Issuance of September 2023 warrants (Note 7b) 250,000 9.00 Issuance of Medigus warrants (Note 8c (i)) 75 1,297.67 (*) Expiration of warrants (11,430 ) 922.98 Exercise of warrants (Note 7a) (26,153 ) 5.124 Balance, October 31, 2023 384,369 $ 7.90 Number of shares to be issued from the exercise of warrants 826,781 (***) (*) Warrants issued with an exercise price of CAD$1,800.00. (**) These warrants convert into 685,883 shares. (***) See note 19(b).
Schedule of Share Purchase Warrants were Outstanding	As of October 31, 2023, the following share purchase warrants were outstanding: Number of Number of shares Exercise price Exercise price (USD) Expiry date 8,333 8,333 C$ 135.00 $ 97.33 April 22, 2024 1,923 1,923 $ 243.75 $ 243.75 November 17, 2027 124,038 566,450 $ 5.124 $ 5.124 April 6, 2028 75 75 C$ 1,800 $ 1,297.67 November 23, 2024 250,000 250,000 $ 9.00 $ 9.00 September 17, 2028 384,369 826,781 (*) (*) See note 19(b).

Stock Options (Tables)

Stock Options (Tables)	12 Months Ended
	Oct. 31, 2023
Notes and other explanatory information [abstract]
Schedule of Changes in Stock Options	The following table summarizes the changes in the Company’s stock options for the years ended October 31, 2023 and October 31, 2022: Number of Weighted (C$) Weighted (USD$) Outstanding, October 31, 2021 3,729 C$ 620.10 $ 455.49 Granted (i) 2,877 620.40 455.71 Cancelled (ii) (1,352 ) 646.80 475.10 Outstanding, October 31, 2022 5,254 C$ 613.5 $ 450.64 Granted (iii, iv, v) 334 442.22 318.81 Outstanding, October 31, 2023 5,588 C$ 603.12 $ 434.81 Exercisable, October 31, 2023 4,039 C$ 606.00 $ 436.89 i) During the year ended October 31, 2022, the Company granted 2,877 stock options to officers, directors and consultants with weighted average exercise price of $455.71 per Common Share. The options vest over 3 years with expiration dates between 5 to 10 years. ii) On July 2, 2022, 222 options canceled with a fair value of $17,649. On May 7, 2022, 1,111 options canceled with a fair value of $92,170. On May 1, 2022 ,19 options canceled with a fair value of $3,959. iii) On May 23, 2023, the Company granted 61 stock options to a consultant of the Company. The options are exercisable at CAD$315.00 (USD$227.09) per share. The options expire on May 23, 2033. iv) On June 26, 2023, the Company granted 223 stock options to a consultant of the Company. The 156 options are exercisable at CAD$504 (USD$363.35) per share and the 67 options are exercisable at CAD$720.00 (USD$519.07) per share. The options expire on June 26, 2033. v) On July 6, 2023, the Company granted 50 stock options to a consultant of the Company. The options are exercisable at $23.40 per share. The options expire on July 6, 2033.
Schedule of Additional Information Regarding Stock Options Outstanding	Additional information regarding stock options outstanding as of October 31, 2023, is as follows: Outstanding Exercisable Number of Weighted Weighted Weighted Number of Weighted Weighted 533 2.57 C$ 166.50 $ 120.03 400 C$ 166.50 $ 120.03 978 8.26 504.00 363.35 667 504.00 363.35 1,166 2.57 675.00 486.63 916 675.00 486.63 200 5.50 702.00 506.09 142 702.00 506.09 133 2.89 747.00 538.53 133 747.00 538.53 422 8.11 612.00 441.21 422 612.00 441.21 1,044 8.26 720.00 519.07 609 720.00 519.07 667 2.67 756.00 545.02 500 756.00 545.02 111 8.11 900.00 648.84 74 900.00 648.84 61 9.57 315.00 227.09 31 315.00 227.09 67 9.66 720.00 519.07 33 720.00 519.07 156 9.66 504.00 363.35 104 504.00 363.35 50 9.69 32.46 23.40 8 32.46 23.40 5,588 5.70 C$ 603.12 $ 434.81 4,039 C$ 606.00 $ 436.89
Schedule of Fair Value of Stock Options	The fair value of stock options previously granted to certain consultants for ongoing services measured during the period have been estimated using the Black-Scholes option pricing model assuming no expected dividends or forfeitures and the following weighted average assumptions: Year ended October 31, 2023 2022 Risk-free interest rate 4.10 % 2.05 % Expected life (in years) 5.61 8.67 Expected volatility 140.41-160.81 % 94.09 %

Restricted Share Units (Tables)

Restricted Share Units (Tables)	12 Months Ended
	Oct. 31, 2023
Restricted Share Units [Abstract]
Schedule of Changes in RSUs	The following table summarizes the changes in RSUs: Number of Weighted Weighted Balance, October 31, 2021 – $ – $ – Granted 1,177 316.50 232.48 Vested (1,177 ) 316.50 232.48 Balance, October 31, 2022 – $ – $ – Granted (i) 2,200 55.97 41.46 Vested (2,200 ) 55.97 41.46 Balance, October 31, 2023 – $ – $ –

Financial Instruments and Ris_2

Financial Instruments and Risk Management (Tables)	12 Months Ended
	Oct. 31, 2023
Financial Instruments and Risk Management [Abstract]
Schedule of Assets and Liabilities Measured at Fair Value	Assets and liabilities measured at fair value on a recurring basis were presented on the Company’s statement of financial position as of October 31, 2023, as follows: Fair Value Measurements Using Quoted prices Significant Significant Balance Short-term investment $ 86,112 $ – $ – $ 86,112 Derivative warrants liability – – 4,310,379 4,310,379 Fair Value Measurements Using Quoted prices Significant Significant Balance Short-term investment $ 193,750 $ – $ – $ 193,750 Derivative liability – 290,569 – 290,569
Schedule of Foreign Currency Exchange Risk on Net Working Capital	The following table indicates the impact of foreign currency exchange risk on net working capital as of October 31, 2023. The table below also provides a sensitivity analysis of a 10% strengthening of the foreign currency against functional currencies identified which would have increased (decreased) the Company’s net loss by the amounts shown in the table below. A 10% weakening of the foreign currency against the functional currencies would have had the equal but opposite effect as of October 31, 2023. Cash $ 78,503 Amounts receivable 104,320 Accounts payable and accrued liabilities (177,226 ) Due to related parties (42,433 ) Total foreign currency financial assets and liabilities $ (36,836 ) Impact of a 10% strengthening or weakening of foreign exchange rate $ (3,684 )
Schedule of Contractual Maturities of Financial Liabilities	The following amounts are the contractual maturities of financial liabilities as of October 31, 2023 and 2022: October 31, 2023 Total Within Within Accounts payable and accrued liabilities $ 617,004 $ 617,004 $ – Due to related parties 42,433 42,433 – $ 659,437 $ 659,437 $ – October 31, 2022 Total Within Within Accounts payable and accrued liabilities $ 1,396,960 $ 1,396,960 $ – Due to related parties 206,494 206,494 – Lease liability 38,390 38,390 – $ 1,641,844 $ 1,641,844 $ –

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Oct. 31, 2023
Income Taxes Table [abstract]
Schedule of Deferred Income Tax Assets and Liabilities	The tax effect (computed by applying the Canadian federal and provincial statutory rate) of the significant differences, which comprise deferred income tax assets and liabilities, are as follows: 2023 2022 2021 Canadian statutory income tax rate 27 % 27 % 27 % Income tax recovery at statutory rate (2,322,936 ) (1,861,476 ) (771,373 ) Tax effect of: Permanent differences and other 204,134 335,494 (3,255 ) Tax rate difference for foreign jurisdiction 10,715 56,175 40,185 Change in unrecognized deferred income tax assets 2,125,459 1,499,666 734,443 Income tax provision 17,372 29,859 -
Schedule of Canadian Non-Capital Losses Carried Forward	As of October 31, 2023, the Company has Canadian non-capital losses carried forward of $13,176,000, which is available to offset future years’ taxable income in Canada. These losses expire as follows: $ 2037 4,085 2038 75,465 2039 73,535 2040 175,671 2041 1,183,266 2042 4,887,566 2043 6,775,908 13,176,216

General and Administrative Ex_2

General and Administrative Expenses (Tables)	12 Months Ended
	Oct. 31, 2023
General and Administrative Expenses [Abstract]
Schedule of General and Administrative Expenses	Year ended Year ended Year ended October 31, October 31, October 31, 2023 2022 2021 Professional fees $ 2,210,795 $ 1,093,871 $ 480,630 Investor relations 1,565,970 473,106 114,706 Share-based compensation (Notes 6, 10 and 11) 243,717 946,324 619,939 Consulting fees (Note 6) 96,421 192,448 521,739 Insurance 364,059 149,537 103,096 Transfer agent and regulatory fees 171,439 86,605 42,492 Depreciation of ROU asset 35,381 60,665 - Salaries and benefits (Note 6) 37,838 92,296 297,188 Office and miscellaneous 31,670 68,016 38,069 Depreciation of property and equipment 1,915 7,572 1,886 Total general and administrative $ 4,759,205 $ 3,170,440 $ 2,219,745

Research and Development (Table

Research and Development (Tables)	12 Months Ended
	Oct. 31, 2023
Research and Development Table [abstract]
Schedule of Research and Development	Year ended Year ended Year ended October 31, October 31, October 31, 2023 2022 2021 Research and preclinical studies $ 1,159,147 $ 2,380,942 $ - Salaries, regulatory, professional and other expenses 469,667 666,125 473,652 Share-based compensation (Notes 6, 10 and 11) 45,870 213,299 - Reimbursements (Note 6) (141,409 ) (194,205 ) - Amortization of intangible assets 10,954 14,830 - Total research and development, net $ 1,544,229 $ 3,080,991 $ 473,652

Nature of Operations and Goin_2

Nature of Operations and Going Concern (Details) - USD ($)					1 Months Ended		12 Months Ended
	Apr. 06, 2023	Apr. 06, 2023	Nov. 14, 2022	Sep. 30, 2022	Jan. 16, 2024	Sep. 18, 2023	Oct. 31, 2023	Oct. 31, 2022
Nature of Operations and Going Concern (Details) [Line Items]
Aggregate gross proceeds	$ 3,500,000	$ 3,500,000	$ 7,500,000		$ 2,400,000	$ 2,250,000
Net proceeds	$ 2,900,000						$ 2,936,079
Accumulated deficit							$ (18,768,063)	$ (10,147,226)
Common shares received per share (in Dollars per share)				$ 0.0333
Description of currency exchange rate							The change in the functional currency was accounted for prospectively from the date of the change by translating all items of the financial statement into the new functional currency using the exchange rate of $0.7327 CAD/USD at the date of the change.
Going concern [Member]
Nature of Operations and Going Concern (Details) [Line Items]
Net proceeds						$ 1,800,000
Negative cash flow							$ 6,301,472
Accumulated deficit							$ 18,768,063

Significant Accounting Polici_3

Significant Accounting Policies (Details) - USD ($)	12 Months Ended
	Oct. 31, 2023	Oct. 31, 2022	Oct. 31, 2021	Jun. 30, 2023
Significant Accounting Policies [Abstract]
Ownership percentage	100%
Maturity period	3 months
Lease liabilities percentage				20%
Defined contribution plans expense	$ 13,988	$ 31,157	$ 50,661
Dilutive shares outstanding	833,810	26,419	21,507

Significant Accounting Polici_4

Significant Accounting Policies (Details) - Schedule of Property and Equipment Estimated Useful Lives	12 Months Ended
	Oct. 31, 2023
Research and Development Equipment [Member]
Significant Accounting Policies (Details) - Schedule of Property and Equipment Estimated Useful Lives [Line Items]
Estimated useful lives	3 years
Computer Equipment [Member]
Significant Accounting Policies (Details) - Schedule of Property and Equipment Estimated Useful Lives [Line Items]
Estimated useful lives	3 years

Intangible Assets (Details)

Intangible Assets (Details)	May 04, 2021 USD ($)
Intangible Assets [Line Items]
Paid salaries	$ 160,000
Estimated remaining life	14 years 7 months 6 days

Leases (Details)

Leases (Details)	12 Months Ended
	Oct. 31, 2023 USD ($)	Oct. 31, 2023 ILS (₪)
Leases [Line Items]
Rent increased	$ 6,500	₪ 23,300
Short-term deposit	$ 33,000
2021 Lease [Member]
Leases [Line Items]
Extend lease description	The Company, Scisparc and the third party had an option to extend the 2021 Lease for an additional three-year period. The Company’s base rent was ILS11,000 per month ($3,080) during the term of the 2021 Lease.	The Company, Scisparc and the third party had an option to extend the 2021 Lease for an additional three-year period. The Company’s base rent was ILS11,000 per month ($3,080) during the term of the 2021 Lease.
Estimated incremental borrowing percentage	20%
Rent increased	$ 5,094	₪ 18,200

Leases (Details) - Schedule of

Leases (Details) - Schedule of ROU office space	12 Months Ended
	Oct. 31, 2023 USD ($)
Schedule of ROU Office Space[Abstract]
Balance at beginning	$ 35,730
Addition
Accumulated depreciation	(35,381)
Foreign currency fluctuation	(349)
Balance at ending

Leases (Details) - Schedule o_2

Leases (Details) - Schedule of Lease Liability - 12 months ended Oct. 31, 2023	USD ($)	CAD ($)
Schedule Of Lease Liability Abstract
Balance at beginning	$ 38,390	$ 38,390
Addition
Lease payments	(40,922)
Interest expense	2,907
Foreign currency translation	(375)
Balance at ending

Leases (Details) - Schedule o_3

Leases (Details) - Schedule of Amounts Recognized in Profit or Loss - USD ($)	12 Months Ended
	Oct. 31, 2023	Oct. 31, 2022	Oct. 31, 2021
Schedule Of Amounts Recognized In Profit Or Loss Abstract
Depreciation	$ 35,381	$ 60,665
Interest	2,907
Foreign currency fluctuation	722
Total amounts recognized in profit or loss	$ 39,010

Short-term Investment (Details)

Short-term Investment (Details) - USD ($)	12 Months Ended
	Oct. 31, 2023	Feb. 14, 2022
Short-term Investment (Details) [Line Items]
Percentage of share holding	0.11%
Total fair value (in Dollars)	$ 86,112
Medigus Ltd [Member]
Short-term Investment (Details) [Line Items]
Ordinary shares received	27,778	27,778

Short-term Investment (Detail_2

Short-term Investment (Details) - Schedule of Fair Value of Common Shares - Medigus Ltd One [Member] - USD ($)	12 Months Ended
	Oct. 31, 2023	Oct. 31, 2022
Schedule of Fair Value of Common Shares [Line Items]
Medigus Ltd. – Shares, Balance Beginning	193,750
Medigus Ltd. – Shares, Additions		$ 501,938
Medigus Ltd. – Shares, Unrealized loss	$ (107,638)	$ (308,188)
Medigus Ltd. – Shares, Balance Ending	86,112	193,750

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	12 Months Ended
	Oct. 31, 2023	Oct. 31, 2022	Oct. 31, 2021
Related Party Transactions [Abstract]
Proceed joint venture percentage	50%
Received reimbursement
Owed to the Company	$ 136,002	$ 46,988
SciSparc Ltd [Member]
Related Party Transactions [Abstract]
Proceed joint venture percentage	50%
Received reimbursement	$ 131,409	$ 194,205

Related Party Transactions (D_2

Related Party Transactions (Details) - Schedule of Key Management Personnel for Employment Services - USD ($)	12 Months Ended
	Oct. 31, 2023	Oct. 31, 2022	Oct. 31, 2021
Officers:
Officers management	$ 534,874	$ 1,258,838	$ 527,004
Directors:
Directors employment services	304,242	168,231	55,316
Payroll and other short-term benefits [Member]
Officers:
Officers management		32,533	297,188
Consulting fees [Member]
Officers:
Officers management	410,066	453,519	49,820
Share based compensation [Member]
Officers:
Officers management	124,808	772,786	179,996
Directors:
Directors employment services	121,981	43,485	17,218
Directors’ fees [Member]
Directors:
Directors employment services	$ 182,261	$ 124,746	$ 38,098

Related Party Transactions (D_3

Related Party Transactions (Details) - Schedule of Balances with Related Parties - CAD ($)	12 Months Ended
	Oct. 31, 2023	Oct. 31, 2022
Schedule of Balances with Related Parties [Abstract]
Amounts owed to officers	$ 29,666	$ 136,149
Amounts owed to directors	12,767	70,345
Total amounts owed	$ 42,433	$ 206,494

Derivative Warrants Liabiliti_3

Derivative Warrants Liabilities (Details) - USD ($)					12 Months Ended
	Oct. 20, 2023	Sep. 24, 2023	Sep. 18, 2023	Apr. 06, 2023	Oct. 31, 2023	Oct. 31, 2022	Oct. 31, 2021
Derivative Warrants Liabilities (Details) [Line Items]
Issued of warrants (in Shares)			250,000
Exercise price per share (in Dollars per share)		$ 5.124
Fair value	$ 574,040	$ 26,153			$ 1,164,117
Common shares issued	$ 119,433				296,569
Derivative warrants liability					$ 2,189,986	$ 290,569
Warrants [Member]
Derivative Warrants Liabilities (Details) [Line Items]
Issued of warrants (in Shares)				150,191
Derivative warrants liability			$ 2,189,986

Derivative Warrants Liabiliti_4

Derivative Warrants Liabilities (Details) - Schedule of Binomial Model was Used to Measure the Derivative Warrant Liability - $ / shares		12 Months Ended
	Nov. 14, 2023	Oct. 31, 2023	Oct. 31, 2022
Derivative Warrants Liabilities (Details) - Schedule of Binomial Model was Used to Measure the Derivative Warrant Liability [Line Items]
Risk-free interest rate		4.10%	2.05%
Dividend yield	20%	0%
Bottom of range [member]
Derivative Warrants Liabilities (Details) - Schedule of Binomial Model was Used to Measure the Derivative Warrant Liability [Line Items]
Share Price (in Dollars per share)		$ 3.66
Exercise Price (in Dollars per share)		$ 5.12
Expected life		4 years 5 months 4 days
Risk-free interest rate		3.37%
Expected volatility		74.79%
Top of range [member]
Derivative Warrants Liabilities (Details) - Schedule of Binomial Model was Used to Measure the Derivative Warrant Liability [Line Items]
Share Price (in Dollars per share)		$ 11.52
Exercise Price (in Dollars per share)		$ 23.4
Expected life		5 years
Risk-free interest rate		4.95%
Expected volatility		157.70%

Derivative Warrants Liabiliti_5

Derivative Warrants Liabilities (Details) - Schedule of Changes in the Warrants Liability	12 Months Ended
	Oct. 31, 2023 USD ($)
Derivative Warrants Liabilities (Details) - Schedule of Changes in the Warrants Liability [Line Items]
Balance at beginning
Issuance of Warrants	1,771,208
Balance at ending	4,310,379
Warrants [member]
Derivative Warrants Liabilities (Details) - Schedule of Changes in the Warrants Liability [Line Items]
Balance at beginning
Issuance of Warrants	923,225
Exercise of warrants	(574,040)
Changes in fair value of warrants	2,189,986
Balance at ending	$ 4,310,379

Share Capital (Details)

Share Capital (Details)														1 Months Ended					12 Months Ended
	Sep. 18, 2023 USD ($) $ / shares shares	Aug. 28, 2023 USD ($) shares	Jul. 10, 2023 USD ($) shares	Jun. 01, 2023 USD ($) shares	May 23, 2023 USD ($) shares	Apr. 06, 2023 USD ($) $ / shares shares	Apr. 06, 2023 USD ($) $ / shares shares	Feb. 22, 2023 USD ($) shares	Jan. 16, 2023 USD ($) shares	Nov. 14, 2022 USD ($) $ / shares	Nov. 14, 2022 USD ($) $ / shares shares	Feb. 14, 2022 USD ($) $ / shares	Apr. 09, 2021 CAD ($) $ / shares shares	Jan. 16, 2024 USD ($)	Sep. 18, 2023 USD ($) $ / shares shares	Feb. 14, 2022 USD ($) shares	Feb. 14, 2022 CAD ($) $ / shares shares	Jul. 22, 2021 CAD ($) $ / shares shares	Oct. 31, 2023 USD ($) $ / shares shares	Oct. 31, 2022 USD ($) shares	Oct. 31, 2022 CAD ($) shares	Oct. 31, 2022 CAD ($) shares	Jun. 22, 2022 shares	Nov. 26, 2021 CAD ($) shares	Oct. 31, 2021 shares
Share Capital (Details) [Line Items]
Number of shares issued		44	597	245	1,494	5	5	400	161														75		607,337
Number of shares outstanding																				43,992		43,992
Issuance of common share											38,462
Purchase price per share (in Dollars per share) | $ / shares										$ 195	$ 195								$ 195
Aggregate gross proceeds (in Dollars) | $						$ 3,500,000	$ 3,500,000			$ 7,500,000				$ 2,400,000	$ 2,250,000
Net proceeds from offering post (in Dollars) | $										$ 6,363,906	$ 6,363,906
Additional common shares																			5,769
Common shares percentage																			15%
Received underwriter warrants																			1,923
Fair value of underwriter warrants (in Dollars) | $																			$ 337,579
Warrants shares																				2,208	2,208
Fair value of issuance in shareholder equity (in Dollars) | $					$ (296,845)
Fair value of RSU (in Dollars) | $		$ 65,143		$ 48,194				$ 110,096	$ 39,975
Underwritten public offering	225,833						103,249
Per share (in Dollars per share) | $ / shares	$ 9					$ 23.4	$ 23.4								$ 9
Warrants purchase							46,942								24,167
Pre funded warrant (in Dollars per share) | $ / shares							$ 23.37								$ 8.97
Pre Funded Warrant Exercisable (in Dollars per share) | $ / shares						$ 0.03									$ 0.03
Common Shares Exercised (in Dollars per share) | $ / shares	119,433						23.4
Exercise Price of Warrants Reduced (in Dollars per share) | $ / shares							$ 5.124
Warrant convertible common shares							4.6
Net proceeds (in Dollars) | $							$ 2,900,000												$ 2,936,079
Shares issued					239								11,111				45	9,222						44
Common shares fair value		$ 607	$ 10,000		$ 110,000																$ 372,745
Expire years (in Dollars per share) | $ / shares	5
Common share (in Dollars per share) | $ / shares	$ 9
Net proceeds from offerings (in Dollars) | $	$ 1,814,193														$ 1,814,193
Warrant Shares	26,153
Fair Value of Warrants (in Dollars) | $	$ 574,040
Fair value (in Dollars) | $																	$ 17,584							$ 21,100
Consideration amount																$ 750,000	$ 27,778
One common shares																1	1	1
One share purchase warrant																1	1	1
Warrant exercisable (in Dollars per share) | $ / shares																	$ 60	$ 824.24
Price per units | (per share)												$ 720						$ 494.54
Proceeds for issue amounts (in Dollars) | $												$ 698,897
Finder’s fee | $													$ 85,857					$ 435,197
Fair value warrant (in Dollars) | $																					$ 82,742
Risk-free rate																			4.10%	2.05%	2.05%
Volatility																				94.09%	94.09%
Derivative financial liability (in Dollars)																				$ 290,569		$ 290,569
Prices per share (in Dollars per share) | $ / shares													$ 98.91
Gross proceeds (in Dollars) | $													$ 1,098,982					$ 4,560,773
Option pricing model [member]
Share Capital (Details) [Line Items]
Risk-free rate																			1.43%	1.43%	1.43%
Expected life																				1 year 6 months	1 year 6 months
Volatility																			150%	107.46%	107.46%
Medigus [Member]
Share Capital (Details) [Line Items]
Number of shares issued					1,494
Warrants [member]
Share Capital (Details) [Line Items]
Warrants shares					75
Common Shares [Member]
Share Capital (Details) [Line Items]
Number of shares issued		585
Share price (in Dollars per share) | $ / shares																			$ 243.75
Common shares fair value | $					$ 27,965
Warrants [member]
Share Capital (Details) [Line Items]
Number of shares issued																							1,494
Cash Financing [Member]
Share Capital (Details) [Line Items]
Shares issued																	2,208		1,325
Finder’s fee | $																					$ 69,890
Share Exchange Agreement [Member]
Share Capital (Details) [Line Items]
Shares issued																				883		883
Fair value (in Dollars) | $																						$ 455,487
Finder’s fee | $																				$ 50,000

Share Capital (Details) - Sched

Share Capital (Details) - Schedule of the Fair Value has been Estimated using the Black-Scholes - Option pricing model [member]	12 Months Ended
	Oct. 31, 2023	Oct. 31, 2022
Share Capital (Details) - Schedule of the Fair Value has been Estimated using the Black-Scholes [Line Items]
Risk-free interest rate	1.43%	1.43%
Expected life (in years)	5 years
Expected volatility	150%	107.46%

Share Purchase Warrants (Detail

Share Purchase Warrants (Details)		12 Months Ended
	Feb. 14, 2022 $ / shares	Oct. 31, 2023 USD ($) shares	Oct. 31, 2023 CAD ($) shares	Oct. 31, 2022 USD ($)	Oct. 31, 2021 USD ($)
Share Purchase Warrants [Abstract]
Warrants issued with exercise price		$ 590,077	$ 1,800
Warrants convert into shares | shares		685,883	685,883
Warrant exercisable price per share | $ / shares	$ 1,297.67

Share Purchase Warrants (Deta_2

Share Purchase Warrants (Details) - Schedule of Share Purchase Warrants - $ / shares		12 Months Ended
		Oct. 31, 2023	Oct. 31, 2022
Schedule Of Share Purchase Warrants Abstract
Number of warrants, Balance beginning		19,763	17,555
Weighted average exercise price, Balance beginning (in Dollars per share)		$ 576.66	$ 482.55
Number of warrants, Issued (i)			2,208
Weighted average exercise price, Issued (i)	[1]		1,325.67
Number of warrants, Balance ending		384,369	19,763
Weighted average exercise price, Balance ending (in Dollars per share)		$ 7.9	$ 576.66
Number of warrants, Number of shares to be issued from the exercise of warrants	[2]	826,781
Number of warrants, Issuance of underwriter warrants (Note 8c (i))		1,923
Weighted average exercise price, Issuance of underwriter warrants (Note 8c (i))		243.75
Number of warrants, Issuance of April 2023 warrants (Note 7a)	[3]	150,191
Weighted average exercise price,Issuance of April 2023 warrants (Note 7a) (in Dollars per share)		$ 5.124
Number of warrants, Issuance of warrants		250,000
Weighted average exercise price, Issuance of warrants (in Dollars per share)		$ 9
Number of warrants, Issuance of Medigus warrants (Note 8c (i))		75
Weighted average exercise price, Issuance of Medigus warrants (Note 8c (i))	[1]	1,297.67
Number of warrants, Expiration of warrants		(11,430)
Weighted average exercise price, Expiration of warrants		922.98
Number of warrants, Exercise of warrants (Note 7a)		(26,153)
Weighted average exercise price, Exercise of warrants (Note 7a) (in Dollars per share)		$ 5.124
[1]Warrants issued with an exercise price of CAD$1,800.00.[2]See note 19(b).[3]These warrants convert into 685,883 shares.

Share Purchase Warrants (Deta_3

Share Purchase Warrants (Details) - Schedule of Share Purchase Warrants were Outstanding - Oct. 31, 2023		$ / shares shares	$ / shares shares
Share Purchase Warrants (Details) - Schedule of Share Purchase Warrants were Outstanding [Line Items]
Number of warrants outstanding		384,369	384,369
Number of shares to be issued from the exercise of warrants	[1]	826,781	826,781
Number of warrants outstanding [Member]
Share Purchase Warrants (Details) - Schedule of Share Purchase Warrants were Outstanding [Line Items]
Number of warrants outstanding		8,333	8,333
Number of shares to be issued from the exercise of warrants		8,333	8,333
Exercise price (in Dollars per share) | (per share)		$ 97.33	$ 135
Exercise price (USD) (in Dollars per share) | (per share)		$ 97.33	$ 135
Expiry date		Apr. 22, 2024	Apr. 22, 2024
Number of shares to be issued from the exercise of warrants [Member]
Share Purchase Warrants (Details) - Schedule of Share Purchase Warrants were Outstanding [Line Items]
Number of warrants outstanding		1,923	1,923
Number of shares to be issued from the exercise of warrants		1,923	1,923
Exercise price (in Dollars per share) | (per share)		$ 243.75	$ 243.75
Exercise price (USD) (in Dollars per share) | (per share)		$ 243.75	$ 243.75
Expiry date		Nov. 17, 2027	Nov. 17, 2027
Exercise price [Member]
Share Purchase Warrants (Details) - Schedule of Share Purchase Warrants were Outstanding [Line Items]
Number of warrants outstanding		124,038	124,038
Number of shares to be issued from the exercise of warrants		566,450	566,450
Exercise price (in Dollars per share) | (per share)		$ 5.124	$ 5.124
Exercise price (USD) (in Dollars per share) | (per share)		$ 5.124	$ 5.124
Expiry date		Apr. 06, 2028	Apr. 06, 2028
Exercise price (USD) [Member]
Share Purchase Warrants (Details) - Schedule of Share Purchase Warrants were Outstanding [Line Items]
Number of warrants outstanding		75	75
Number of shares to be issued from the exercise of warrants		75	75
Exercise price (in Dollars per share) | (per share)		$ 1,297.67	$ 1,800
Exercise price (USD) (in Dollars per share) | (per share)		$ 1,297.67	$ 1,800
Expiry date		Nov. 23, 2024	Nov. 23, 2024
Expiry date [Member]
Share Purchase Warrants (Details) - Schedule of Share Purchase Warrants were Outstanding [Line Items]
Number of warrants outstanding		250,000	250,000
Number of shares to be issued from the exercise of warrants		250,000	250,000
Exercise price (in Dollars per share) | (per share)		$ 9	$ 9
Exercise price (USD) (in Dollars per share) | (per share)		$ 9	$ 9
Expiry date		Sep. 17, 2028	Sep. 17, 2028
[1]See note 19(b).

Stock Options (Details)

Stock Options (Details)						1 Months Ended				12 Months Ended
	Jul. 06, 2023 $ / shares	Jul. 02, 2022	May 07, 2022	May 01, 2022	Sep. 01, 2021	Jun. 26, 2023 $ / shares	Jun. 26, 2023 $ / shares	May 23, 2023 $ / shares	May 23, 2023 $ / shares	Oct. 31, 2023 USD ($)	Oct. 31, 2023 CAD ($)	Oct. 31, 2022 USD ($) $ / shares shares	Oct. 31, 2022 CAD ($) shares	Oct. 31, 2021 USD ($)
Stock Options (Details) [Line Items]
Description of stock options					The Board is authorized to grant the maximum number of common shares reserved for issuance in any 12-month period to anyone, optionee, other than a consultant may not exceed 5% of the issued and outstanding common shares at the date of the grant. The maximum number of common shares reserved for issuance in any 12-month period to any consultant may not exceed 2% of the issued and outstanding common shares at the date of the grant and the maximum number of common shares reserved for issuance in any 12-month period to all persons engaged in investor relations activities may not exceed 2% of the issued and outstanding number of common shares at the date of the grant.
Stock options granted (in Shares) | shares												2,877	2,877
Weighted average exercise price per share (in Dollars per share) | $ / shares												$ 455.71
Options vest expiration												3 years	3 years
Options canceled		222	1,111	19
Options canceled		17,649	92,170	3,959
Stock options to consultant	50					223	223	61	61
Options are exercisable | (per share)	$ 23.4					$ 363.35	$ 504	$ 227.09	$ 315
Options are exercisable						156	156
Share-based compensation expense. (in Dollars)										$ 243,717	$ 221,625	$ 946,324	$ 788,657	$ 619,939
Bottom of range [Member]
Stock Options (Details) [Line Items]
Options vest expiration												5 years	5 years
Top of range [Member]
Stock Options (Details) [Line Items]
Options vest expiration												10 years	10 years
Share options [Member]
Stock Options (Details) [Line Items]
Options are exercisable | (per share)						$ 519.07	$ 720
Options are exercisable						67	67

Stock Options (Details) - Sched

Stock Options (Details) - Schedule of Changes in Stock Options		12 Months Ended
		Oct. 31, 2023 $ / shares shares		Oct. 31, 2023 $ / shares $ / shares shares		Oct. 31, 2022 $ / shares shares		Oct. 31, 2022 $ / shares shares		Oct. 31, 2023 $ / shares
Schedule of Changes in the Company’s Stock Options [Abstract]
Number of options Outstanding, Beginning balance		5,254		5,254		3,729		3,729
Weighted average exercise price Outstanding, Beginning balance | (per share)		$ 450.64		$ 613.5		$ 455.49		$ 620.1
Number of options, Granted		334	[1],[2],[3]	334	[1],[2],[3]	2,877	[4]	2,877	[4]
Weighted average exercise price, Granted | (per share)		$ 318.81	[2],[3]	$ 442.22	[2],[3]	$ 455.71	[4]	$ 620.4	[4]
Number of options, Cancelled	[5]					(1,352)		(1,352)
Weighted average exercise price, Cancelled | (per share)	[5]					$ 475.1		$ 646.8
Number of options Outstanding, Ending balance		5,588		5,588		5,254		5,254
Weighted average exercise price Outstanding, Ending balance | (per share)		$ 434.81		$ 603.12		$ 450.64		$ 613.5
Number of options Outstanding, Exercisable		4,039		4,039
Weighted average exercise price Outstanding, Exercisable | (per share)		$ 436.89		$ 436.89						$ 606
[1] On June 26, 2023, the Company granted 223 stock options to a consultant of the Company. The 156 options are exercisable at CAD$504 (USD$363.35) per share and the 67 options are exercisable at CAD$720.00 (USD$519.07) per share. The options expire on June 26, 2033.

Stock Options (Details) - Sch_2

Stock Options (Details) - Schedule of Additional Information Regarding Stock Options Outstanding - 12 months ended Oct. 31, 2023	$ / shares shares	$ / shares shares
Stock Outstanding [Member]
Stock Options (Details) - Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Outstanding	5,588	5,588
Weighted average remaining contractual life (years) Outstanding	5 years 8 months 12 days	5 years 8 months 12 days
Weighted average exercise price Outstanding | (per share)	$ 434.81	$ 603.12
Stock Outstanding [Member] | 533 [Member]
Stock Options (Details) - Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Outstanding	533	533
Weighted average remaining contractual life (years) Outstanding	2 years 6 months 25 days	2 years 6 months 25 days
Weighted average exercise price Outstanding | (per share)	$ 120.03	$ 166.5
Stock Outstanding [Member] | 978 [Member]
Stock Options (Details) - Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Outstanding	978	978
Weighted average remaining contractual life (years) Outstanding	8 years 3 months 3 days	8 years 3 months 3 days
Weighted average exercise price Outstanding | (per share)	$ 363.35	$ 504
Stock Outstanding [Member] | 1,166 [Member]
Stock Options (Details) - Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Outstanding	1,166	1,166
Weighted average remaining contractual life (years) Outstanding	2 years 6 months 25 days	2 years 6 months 25 days
Weighted average exercise price Outstanding | (per share)	$ 486.63	$ 675
Stock Outstanding [Member] | 200 [Member]
Stock Options (Details) - Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Outstanding	200	200
Weighted average remaining contractual life (years) Outstanding	5 years 6 months	5 years 6 months
Weighted average exercise price Outstanding | (per share)	$ 506.09	$ 702
Stock Outstanding [Member] | 133 [Member]
Stock Options (Details) - Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Outstanding	133	133
Weighted average remaining contractual life (years) Outstanding	2 years 10 months 20 days	2 years 10 months 20 days
Weighted average exercise price Outstanding | (per share)	$ 538.53	$ 747
Stock Outstanding [Member] | 422 [Member]
Stock Options (Details) - Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Outstanding	422	422
Weighted average remaining contractual life (years) Outstanding	8 years 1 month 9 days	8 years 1 month 9 days
Weighted average exercise price Outstanding | (per share)	$ 441.21	$ 612
Stock Outstanding [Member] | 1,044 [Member]
Stock Options (Details) - Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Outstanding	1,044	1,044
Weighted average remaining contractual life (years) Outstanding	8 years 3 months 3 days	8 years 3 months 3 days
Weighted average exercise price Outstanding | (per share)	$ 519.07	$ 720
Stock Outstanding [Member] | 667 [Member]
Stock Options (Details) - Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Outstanding	667	667
Weighted average remaining contractual life (years) Outstanding	2 years 8 months 1 day	2 years 8 months 1 day
Weighted average exercise price Outstanding | (per share)	$ 545.02	$ 756
Stock Outstanding [Member] | 111 [Member]
Stock Options (Details) - Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Outstanding	111	111
Weighted average remaining contractual life (years) Outstanding	8 years 1 month 9 days	8 years 1 month 9 days
Weighted average exercise price Outstanding | (per share)	$ 648.84	$ 900
Stock Outstanding [Member] | 61 [Member]
Stock Options (Details) - Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Outstanding	61	61
Weighted average remaining contractual life (years) Outstanding	9 years 6 months 25 days	9 years 6 months 25 days
Weighted average exercise price Outstanding | (per share)	$ 227.09	$ 315
Stock Outstanding [Member] | 67 [Member]
Stock Options (Details) - Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Outstanding	67	67
Weighted average remaining contractual life (years) Outstanding	9 years 7 months 28 days	9 years 7 months 28 days
Weighted average exercise price Outstanding | (per share)	$ 519.07	$ 720
Stock Outstanding [Member] | 156 [Member]
Stock Options (Details) - Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Outstanding	156	156
Weighted average remaining contractual life (years) Outstanding	9 years 7 months 28 days	9 years 7 months 28 days
Weighted average exercise price Outstanding | (per share)	$ 363.35	$ 504
Stock Outstanding [Member] | 50 [Member]
Stock Options (Details) - Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Outstanding	50	50
Weighted average remaining contractual life (years) Outstanding	9 years 8 months 8 days	9 years 8 months 8 days
Weighted average exercise price Outstanding | (per share)	$ 23.4	$ 32.46
Stock Exercisable [Member]
Stock Options (Details) - Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Exercisable	4,039	4,039
Weighted average exercise price, Exercisable | (per share)	$ 436.89	$ 606
Stock Exercisable [Member] | 533 [Member]
Stock Options (Details) - Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Exercisable	400	400
Weighted average exercise price, Exercisable | (per share)	$ 120.03	$ 166.5
Stock Exercisable [Member] | 978 [Member]
Stock Options (Details) - Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Exercisable	667	667
Weighted average exercise price, Exercisable | (per share)	$ 363.35	$ 504
Stock Exercisable [Member] | 1,166 [Member]
Stock Options (Details) - Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Exercisable	916	916
Weighted average exercise price, Exercisable | (per share)	$ 486.63	$ 675
Stock Exercisable [Member] | 200 [Member]
Stock Options (Details) - Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Exercisable	142	142
Weighted average exercise price, Exercisable | (per share)	$ 506.09	$ 702
Stock Exercisable [Member] | 133 [Member]
Stock Options (Details) - Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Exercisable	133	133
Weighted average exercise price, Exercisable | (per share)	$ 538.53	$ 747
Stock Exercisable [Member] | 422 [Member]
Stock Options (Details) - Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Exercisable	422	422
Weighted average exercise price, Exercisable | (per share)	$ 441.21	$ 612
Stock Exercisable [Member] | 1,044 [Member]
Stock Options (Details) - Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Exercisable	609	609
Weighted average exercise price, Exercisable | (per share)	$ 519.07	$ 720
Stock Exercisable [Member] | 667 [Member]
Stock Options (Details) - Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Exercisable	500	500
Weighted average exercise price, Exercisable | (per share)	$ 545.02	$ 756
Stock Exercisable [Member] | 111 [Member]
Stock Options (Details) - Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Exercisable	74	74
Weighted average exercise price, Exercisable | (per share)	$ 648.84	$ 900
Stock Exercisable [Member] | 61 [Member]
Stock Options (Details) - Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Exercisable	31	31
Weighted average exercise price, Exercisable | (per share)	$ 227.09	$ 315
Stock Exercisable [Member] | 67 [Member]
Stock Options (Details) - Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Exercisable	33	33
Weighted average exercise price, Exercisable | (per share)	$ 519.07	$ 720
Stock Exercisable [Member] | 156 [Member]
Stock Options (Details) - Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Exercisable	104	104
Weighted average exercise price, Exercisable | (per share)	$ 363.35	$ 504
Stock Exercisable [Member] | 50 [Member]
Stock Options (Details) - Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Exercisable	8	8
Weighted average exercise price, Exercisable | (per share)	$ 23.4	$ 32.46

Stock Options (Details) - Sch_3

Stock Options (Details) - Schedule of Fair Value of Stock Options	12 Months Ended
	Oct. 31, 2023	Oct. 31, 2022
Schedule of Fair Value of Stock Options [Abstract]
Risk-free interest rate	4.10%	2.05%
Expected life (in years)	5 years 7 months 9 days	8 years 8 months 1 day
Expected volatility		94.09%
Bottom of range [Member]
Schedule of Fair Value of Stock Options [Abstract]
Risk-free interest rate	3.37%
Expected volatility	140.41%
Top of range [Member]
Schedule of Fair Value of Stock Options [Abstract]
Risk-free interest rate	4.95%
Expected volatility	160.81%

Restricted Share Units (Details

Restricted Share Units (Details)	12 Months Ended
	Oct. 31, 2023 CAD ($) shares	Oct. 31, 2023 USD ($)	Oct. 31, 2022 USD ($)
Restricted Share Units [Abstract]
RSU issued (in Shares) | shares	2,200
Fair Value of Consultants		$ 91,589	$ 272,985
Share-based compensation payments (in Dollars)	$ 171,819
Share- based payment reserve			$ 380,207

Restricted Share Units (Detai_2

Restricted Share Units (Details) - Schedule of Changes in RSUs - Restricted share units [member]	12 Months Ended
	Oct. 31, 2023 $ / shares shares	Oct. 31, 2023 $ / shares shares	Oct. 31, 2022 $ / shares shares	Oct. 31, 2022 $ / shares shares
Schedule of Changes in RSUs [Line Items]
Number of RSUs, Beginning Balance
Weighted average issue price, Beginning Balance | (per share)
Granted, Number of RSUs	2,200	2,200	1,177	1,177
Granted, Weighted average issue price | (per share)	$ 41.46	$ 55.97	$ 232.48	$ 316.5
Vested, Number of RSUs	(2,200)	(2,200)	(1,177)	(1,177)
Vested, Weighted average issue price | (per share)	$ 41.46	$ 55.97	$ 232.48	$ 316.5
Number of RSUs, Ending Balance
Weighted average issue price, Ending Balance | (per share)

Financial Instruments and Ris_3

Financial Instruments and Risk Management (Details)	1 Months Ended	12 Months Ended
	Oct. 31, 2023	Oct. 31, 2023
Financial Instruments and Risk Management [Abstract]
Foreign currency, percentage	10%	10%

Financial Instruments and Ris_4

Financial Instruments and Risk Management (Details) - Schedule of Assets and Liabilities Measured at Fair Value - USD ($)	Oct. 31, 2023	Oct. 31, 2022
Financial Instruments and Risk Management [Line Items]
Short-term investment	$ 86,112	$ 193,750
Derivative liability		290,569
Derivative warrants liability	4,310,379
Quoted prices in active markets for identical instruments (Level 1) [Member]
Financial Instruments and Risk Management [Line Items]
Short-term investment	86,112	193,750
Derivative liability
Derivative warrants liability
Significant other observable inputs (Level 2) [Member]
Financial Instruments and Risk Management [Line Items]
Short-term investment
Derivative liability		290,569
Derivative warrants liability
Significant unobservable inputs (Level 3) [Member]
Financial Instruments and Risk Management [Line Items]
Short-term investment
Derivative liability
Derivative warrants liability	$ 4,310,379

Financial Instruments and Ris_5

Financial Instruments and Risk Management (Details) - Schedule of Foreign Currency Exchange Risk on Net Working Capital	12 Months Ended
	Oct. 31, 2023 USD ($)
Schedule of Foreign Currency Exchange Risk on Net Working Capital [Abstract]
Cash	$ 78,503
Amounts receivable	104,320
Accounts payable and accrued liabilities	(177,226)
Due to related parties	(42,433)
Total foreign currency financial assets and liabilities	(36,836)
Impact of a 10% strengthening or weakening of foreign exchange rate	$ (3,684)

Financial Instruments and Ris_6

Financial Instruments and Risk Management (Details) - Schedule of Foreign Currency Exchange Risk on Net Working Capital (Parentheticals)	12 Months Ended
	Oct. 31, 2023
Schedule of Foreign Currency Exchange Risk on Net Working Capital [Abstract]
Impact of a strengthening or weakening of foreign exchange rate	10%

Financial Instruments and Ris_7

Financial Instruments and Risk Management (Details) - Schedule of Contractual Maturities of Financial Liabilities	Oct. 31, 2023 USD ($)	Oct. 31, 2023 CAD ($)	Oct. 31, 2022 USD ($)	Oct. 31, 2022 CAD ($)
Financial Instruments and Risk Management [Line Items]
Accounts payable and accrued liabilities		$ 617,004		$ 1,396,960
Due to related parties		42,433		206,494
Lease liability			$ 38,390	38,390
Total		659,437		1,641,844
Within 1 year [Member]
Financial Instruments and Risk Management [Line Items]
Accounts payable and accrued liabilities		617,004		1,396,960
Due to related parties		42,433		206,494
Lease liability				38,390
Total		659,437		1,641,844
Within 2-5 years [Member]
Financial Instruments and Risk Management [Line Items]
Accounts payable and accrued liabilities
Due to related parties
Lease liability
Total

Income Taxes (Details)

Income Taxes (Details) - USD ($)	12 Months Ended
	Oct. 31, 2023	Oct. 31, 2022	Oct. 31, 2021
Income Taxes (Details) [Line Items]
Provincial statutory income tax rate	27%	27%	27%
Statutory corporate tax rate	23%	23%	23%
Canada [Member]
Income Taxes (Details) [Line Items]
Non-capital losses carried forward (in Dollars)	$ 13,176,000
Israel [Memebr]
Income Taxes (Details) [Line Items]
Non-capital losses carried forward (in Dollars)	$ 2,253,000

Income Taxes (Details) - Schedu

Income Taxes (Details) - Schedule of Deferred Income Tax Assets and Liabilities - USD ($)	12 Months Ended
	Oct. 31, 2023	Oct. 31, 2022	Oct. 31, 2021
Schedule of Deferred Income Tax Assets and Liabilities [Abstract]
Canadian statutory income tax rate	27%	27%	27%
Income tax recovery at statutory rate	$ (2,322,936)	$ (1,861,476)	$ (771,373)
Tax effect of:
Permanent differences and other	204,134	335,494	(3,255)
Tax rate difference for foreign jurisdiction	10,715	56,175	40,185
Change in unrecognized deferred income tax assets	2,125,459	1,499,666	734,443
Income tax provision	$ 17,372	$ 29,859

Income Taxes (Details) - Sche_2

Income Taxes (Details) - Schedule of Canadian Non-Capital Losses Carried Forward	Oct. 31, 2023 USD ($)
Schedule of Canadian Non-Capital Losses Carried Forward [Abstract]
Total non-capital losses carried forward	$ 13,176,216
Two Thousand Thirty Seven [Member]
Schedule of Canadian Non-Capital Losses Carried Forward [Abstract]
Total non-capital losses carried forward	4,085
Two Thousand Thirty Eight [Member]
Schedule of Canadian Non-Capital Losses Carried Forward [Abstract]
Total non-capital losses carried forward	75,465
Two Thousand Thirty Nine [Member]
Schedule of Canadian Non-Capital Losses Carried Forward [Abstract]
Total non-capital losses carried forward	73,535
Two Thousand Forty [Member]
Schedule of Canadian Non-Capital Losses Carried Forward [Abstract]
Total non-capital losses carried forward	175,671
Two Thousand Forty One [Member]
Schedule of Canadian Non-Capital Losses Carried Forward [Abstract]
Total non-capital losses carried forward	1,183,266
Two Thousand Forty Two [Member]
Schedule of Canadian Non-Capital Losses Carried Forward [Abstract]
Total non-capital losses carried forward	4,887,566
Two Thousand Forty Three [Member]
Schedule of Canadian Non-Capital Losses Carried Forward [Abstract]
Total non-capital losses carried forward	$ 6,775,908

General and Administrative Ex_3

General and Administrative Expenses (Details) - Schedule of General and Administrative Expenses	12 Months Ended
	Oct. 31, 2023 USD ($)	Oct. 31, 2023 CAD ($)	Oct. 31, 2022 USD ($)	Oct. 31, 2022 CAD ($)	Oct. 31, 2021 USD ($)
Schedule of General and Administrative Expenses [Abstract]
Professional fees	$ 2,210,795		$ 1,093,871		$ 480,630
Investor relations	1,565,970		473,106		114,706
Share-based compensation	243,717	$ 221,625	946,324	$ 788,657	619,939
Consulting fees	96,421		192,448		521,739
Insurance	364,059		149,537		103,096
Transfer agent and regulatory fees	171,439		86,605		42,492
Depreciation of ROU asset	35,381		60,665
Salaries and benefits	37,838		92,296		297,188
Office and miscellaneous	31,670		68,016		38,069
Depreciation of property and equipment	1,915		7,572		1,886
Total general and administrative	$ 4,759,205		$ 3,170,440		$ 2,219,745

Research and Development (Detai

Research and Development (Details) - Schedule of Research and Development - USD ($)	12 Months Ended
	Oct. 31, 2023	Oct. 31, 2022	Oct. 31, 2021
Schedule of Research and Development [Abstract]
Research and preclinical studies	$ 1,159,147	$ 2,380,942
Salaries, regulatory, professional and other expenses	469,667	666,125	473,652
Share-based compensation (Notes 6, 10 and 11)	45,870	213,299
Reimbursements (Note 6)	(141,409)	(194,205)
Amortization of intangible assets	10,954	14,830
Total research and development, net	$ 1,544,229	$ 3,080,991	$ 473,652

Subsequent Events (Details)

Subsequent Events (Details) - USD ($)										1 Months Ended		12 Months Ended
	Jan. 21, 2024	Jan. 16, 2024	Dec. 05, 2023	Dec. 04, 2023	Nov. 14, 2023	Sep. 18, 2023	Apr. 06, 2023	Apr. 06, 2023	Nov. 14, 2022	Jan. 16, 2024	Sep. 18, 2023	Oct. 31, 2023	Sep. 30, 2023	Apr. 30, 2023
Subsequent Events (Details) [Line Items]
Fair Value of Warrants (in Dollars)						$ 574,040
Purchase of share warrants. (in Shares)							46,942				24,167
Aggregate gross proceeds (in Dollars)							$ 3,500,000	$ 3,500,000	$ 7,500,000	$ 2,400,000	$ 2,250,000
Net proceeds (in Dollars)							$ 2,900,000					$ 2,936,079
Acquire percentage of issued and outstanding					20%							0%
Term award of granted vested					10 years
Non-Adjusting Events After Reporting Period [Member]
Subsequent Events (Details) [Line Items]
Exercise price of warrants													$ 3.181	$ 3.181
Exercise price of convertible warrants (in Shares)			684,315										1,619,768	1,619,768
Exercised shares (in Shares)			221,677	840,511
Fair Value of Warrants (in Dollars)			$ 802,981	$ 2,673,665
Exercise price of adjusted warrants	$ 1.0777		$ 3.6223
Exercise price of adjusted warrants	$ 1,554,991
Common shares (in Shares)		146,800
Public per share		$ 1.5999
Purchase of share warrants. (in Shares)		32,000
Aggregate gross proceeds (in Dollars)		$ 2,400,000
Exercise price per common share		$ 1.6								$ 1.6
Net proceeds (in Dollars)		$ 2,000,000
Non-Adjusting Events After Reporting Period [Member] | Common Shares [Member]
Subsequent Events (Details) [Line Items]
Public per share		$ 1.6
Exercise price of warrants		$ 0.0001